



Introduction to Psychopharmacology
or,
"9,999 Simple Rules for Prescribing
Psychotropics"

L H PASTOR MD
LHPASTORMD@GMAIL.COM

Part 1: Neurotransmitters (NT's): the brain's chemical messengers

EFFECTS OF SPECIFIC NT'S ON SPECIFIC BRAIN FUNCTIONS

UNDERSTAND - DON'T MEMORIZE - SIDE EFFECTS


4 IMPORTANT SIDE EFFECT SYNDROMES (MEMORIZE THESE)



Functional neuroanatomy of depression

Matching:

- | | | |
|--------------------|---|---------------------------|
| ▶ Cognitive Sx | → | Limbic area/Amygdala |
| ▶ Psychomotor Sx | → | Optic chiasm/Pineal Gland |
| ▶ Anhedonic Sx | → | Frontal/prefrontal area |
| ▶ Mood symptoms | → | Basal Ganglia/Striatum |
| ▶ Sleep disruption | → | Nucleus Accumbens |



We're all accustomed to the fact that different brain regions are concerned with different mental and bodily functions. Let's do a little matching test to refresh our memories about what brain regions are associated with various components of clinical depression.

If we could remove the burnt-out part of the brain and replace it, like replacing a burnt-out fuse from the fuse box, that would solve the problem. But we don't generally do brain surgery for depression, so we're left with giving medicines that increase the neurotransmitter molecules that are associated with each brain region, in the hopes of re-activating – or inhibiting – the malfunctioning brain region (next slide).

Symptom categories for depression:

Cognitive Sx = poor concentration, negative cognitive bias (filtering), Attribution bias, "negative cognitive triad"

Somatic Sx = pain, fatigue, HA, stomach upset, sensory changes, heightened pain perception, psychomotor slowing

Anhedonia = favorite meal tastes like cardboard, no interest in favorite activities, loss of sex drive

Mood symptoms = sad, irritable, angry, insecure, guilty, worried, fearful


Sleep disturbance = insomnia or hypersomnia

Overall, it seems short-sighted and limited to call Major Depression a “mood disorder”



Functional neuroanatomy of depression

- ▶ DL-PFC
 - ▶ Attentional control, cognition
 - ▶ Regulation of negative affect
- ▶ VM-PFC
 - ▶ Negative affect
 - ▶ Hyperactive in depression
- ▶ Refractory vs. non-Refractory depression



▶ From "The Functional Neuroanatomy of Depression: Distinct Roles for Ventromedial and Dorsolateral Prefrontal Cortex", Koenigs et al., Behav Brain Res 2009 Aug 12:201(2): 239-243

Review slide.

What is the purpose of the brain, anyway? E.g., the lungs are the organ of oxygen exchange, the kidneys are the organ of filtration, so what is the primary function of the brain? If you said something along the lines of "control and integration center" I couldn't fault you, but I would agree with those who call the brain the organ of "threat detection". What's the real purpose, the survival value, of storing memories, interpreting visual data, generating strong emotions, and so forth, if not to remember to avoid the pile of sticks near the water's edge because that's where the rattlesnake lives, or that the bright red, small berries will make you really sick and kill you, etc.?

The brain as the organ of threat detection makes a lot of sense, from the evolutionary point of view, with all the billions of neurons and trillions of synapses as a kind of complex, giant ciphering machine, that all boils down to a basic, binary decision: approach or avoid, walk toward or run from, seize an opportunity or stay safe.


Because avoiding danger has more survival value than seizing opportunity, the brain has what we all know as – what – the brain's "inherent negativity bias" – that's why

worry and anxiety are normal emotions and not only clinical disorders. Depression and anxiety disorders can be thought of as exaggerations of the brain's normal, inherent negativity bias. The negativity bias refers to the fact that we – i.e., our brains – respond more strongly to a bit of negative news than we do to an equivalent bit of positive news. Eg., we had a lot of positive feedback about something we did, but the one or two little bits of negative feedback are what we zero in on and fixate on. Or, something we said or did years ago that was erroneous or mildly embarrassing comes back to haunt us again and again.

Negativity bias has survival value. After all, which is more important, reaching out and plucking a tasty little berry with healthy carbohydrates and anti-oxidants, or avoiding eating a poisonous little berry that will make you puke and go into muscle spasm and make you lose control of your bowels and bladder before dying a sickening, painful death? Obviously there's more survival value in avoid mortal danger than in securing momentary pleasures. A lot of the field of positive psychology has to do with overcoming the brain's inherent negativity bias, for example, through exercises like savoring, appreciating, looking for the positives, and journaling about the positives. This is especially helpful for patients in treatment for depression, whose brains are hyperalert with negativity bias, always wondering, "what will go wrong next?"

How psychotropics affect brain function

- ▶ Limbic area/Amygdala Serotonin, NE
- ▶ Frontal/prefrontal area 5-HT, Dopamine
- ▶ Hypothalamus Serotonin, Oxytocin
- ▶ Nucleus Accumbens Dopamine
- ▶ Optic chiasm/Pineal Gland Melatonin



From the article “Stress, Neural Plasticity, and Major Depression” in your bibliography, we know, for example, that there’s hypo-activity – as measured by rCBF – in parts of the frontal cortex; and there’s also anatomical changes including reduced cortical thickness and reduced regional volumes.

In MDD, there is specific loss of volume of the hippocampus, as a result of reduced dendritic length and branching in that organelle. In contrast, we see increased dendritic hypertrophy – an increase in connections and activity – in the brain’s alerting and alarm center, the Amygdala.

And of course, other anatomical brain changes, as well. So which neurotransmitters are associated with which brain regions?


How psychotropics affect brain function

- ▶ Limbic area/Amygdala → Serotonin, NE → Mood Symptoms
- ▶ Frontal/prefrontal area → 5-HT, Dopamine → Cognitive Symptoms
- ▶ Hypothalamus → Serotonin → Somatic Symptoms
- ▶ Nucleus Accumbens → Dopamine → Anhedonia, cravings
- ▶ Optic chiasm/Pineal Gland → Melatonin → Sleep disruption

From the article “Stress, Neural Plasticity, and Major Depression” in your bibliography, we know, for example, that there’s hypo-activity – as measured by rCBF – in parts of the frontal cortex; and there’s also anatomical changes including reduced cortical thickness and reduced regional volumes.

In MDD, there is specific loss of volume of the hippocampus, as a result of reduced dendritic length and branching in that organelle. In contrast, we see increased dendritic hypertrophy – an increase in connections and activity – in the brain’s alerting and alarm center, the Amygdala.

And of course, other anatomical brain changes, as well. So which neurotransmitters are associated with which brain regions?



Where we are now:

- Depression: antidepressant
- Anxiety: same “antidepressant”
- Panic disorder: same “antidepressant”
- Eating disorder: again, same “antidepressant”
- Premenstrual dysphoric disorder: same
- PTSD: same
- OCD: same
- Fibromyalgia pain: same
- ADHD: same class of medication
- Migraine HA: same

- Antipsychotic:
 - Schizophrenia
 - Depression in Bipolar disorder
 - Anxiety & insomnia

Therefore: think no longer in outdated terms such as “antidepressant” or


“antipsychotic” or “anti-anxiety” - but rather in terms of the NT type: “Serotonergic”
“Dopaminergic” “Anticholinergic” etc.

Principal DA Pathways in the Brain

Tracts in brain...

- **The Mesolimbic Dopamine Pathway** : midbrain ventral tegmental area to the nucleus accumbens a part of the limbic system of the brain thought to be involved in many behaviors such as pleasurable sensations, the powerful euphoria of drugs of abuse, as well as delusions and hallucinations of psychosis.
- **The Mesocortical Dopamine Pathway** : It also projects from the midbrain ventral tegmental area but sends its axons to areas of the prefrontal cortex, where they may have a role in mediating cognitive symptoms (dorsolateral prefrontal cortex) and affective symptoms (ventromedial prefrontal cortex) of schizophrenia.
- **The Nigrostriatal Dopamine Pathway** : which projects from the substantia nigra to the basal ganglia or striatum, is part of the extrapyramidal nervous system and controls motor function and movement.
- **Tuberoinfundibular Dopamine Pathway** : projects from the hypothalamus to the anterior pituitary gland and controls prolactin secretion.
- **The fifth dopamine pathway arises from multiple sites, including the periaqueductal gray, ventral mesencephalon, hypothalamic nuclei, and lateral parabrachial nucleus, and it projects to the thalamus. Its function is not currently well known.**

Dopamine (DA): 1 Neurotransmitter, many effects




The effect of a psychotropic on the individual depends not only on the characteristics of the drug, and the individual variables in the patient (genetics, presence of essential co-factors in NT synthesis, etc.), but also on which pathways in the brain are affected. For example, if you want to know both the intended effects and the side effects of a DA-blocking drug – a “first generation” antipsychotic – such as Haldol, it helps to know that there are 4 DA pathways in the brain.

And the drug effects correspond to each of the 4 pathways:

- 1) Mesolimbic: pleasure and reward (limbic: VTA & Nacc)
- 2) Mesocortical: hallucinations & delusions (PFC & OFC)
- 3) Nigrostriatal: EPSE and movement disorders (basal ganglia)
- 4) Tuberoinfundibular (HPA axis) – dopamine > VIP > Prolactin > breast milk & mammary glands

Neuroplasticity, Neurogenesis, Synaptoneogenesis



Probably you've all seen by now that two-minute animated video on "neuroplasticity"; or at the very least are familiar with the dictum "neurons that fire together, wire together."

Psychotropic medicines, as well as some micronutrients and supplements, not only increase utilization of specific neurotransmitter messenger molecules, but actually sculpt and reshape the brain itself, through neurogenesis and synaptoneogenesis.


And for extra credit, what was the first "psychological disorder" demonstrated to cause actual, anatomical changes in the size and volume of brain structures?

Ans: PTSD, and "hippocampal atrophy."

Healthy diet = increased hippocampal volume.

Major depression = reduced hippocampal volume, increase in dendritic spine growth in amygdala.



Methamphetamine: effects on DA in the brain



DA, NT are stimulatory NT's.

Amphetamines & cocaine promote massive DA & NT synthesis (cocaine) & release (amphetamine) & can cause long-term depletion or "burnout" of DA & NE pathways.

Ketamine & Lithium growing new synapses "Synaptoneogenesis"



Reference: <http://www.jbrf.org/2012/06/05/how-ketamine-works-to-treat-depression/>, "how ketamine works to treat depression".

Lithium Increases Synapse Formation between Hippocampal Neurons by Depleting Phosphoinositides

Hee Jung Kim and Stanley A. Thayer

Molecular Pharmacology May 2009, 75 (5) 1021-1030; DOI:

<https://doi.org/10.1124/mol.108.052357>

Lithium inhibits GSK3-beta

So, key NT pathways in the brain can be burnt out or depleted by either psychiatric illness or drug abuse, and/or re-grown, via neural plasticity, from recovery or psychotropic medications..

Flower vs. Weed

Dandelions:



Dandelions:



Intended Effect vs. Side Effect

Minoxidil: anti-hypertensive Rx:



Minoxidil: anti-alopecia Rx:



Sometimes the answer is: using a different drug.

Sometimes the answer is: using the same drug, for a different purpose.

In fact, side effects and intended effects – like the DA that goes to four different pathways in the brain, or like the dandelion flower – are one in the same.

Why do we get “side effects” in the first place?

- ▶ (1) all drugs have a variety of effects; the desired effect is called the “intended effect” and all the other effects are deemed “side effects”
 - ▶ (2) the dose is too high, bringing out “dose dependent” side effects
 - ▶ (3) The dose is not too high, but titrated upward too quickly
 - ▶ (4) allergic reactions
 - ▶ (5) Drug-drug interactions
 - ▶ (6) genetic variability (“slow metabolizers”)
 - ▶ (7) medical complications
- ▶ **Take-aways:**
- ▶ 1. Not all people get all possible s/e's of a medication (look for the “discontinuation rate” on the package insert –a proxy for severe s/e's)
 - ▶ 2. There's a difference between side effects (common, expected) vs. Allergic reaction (rare, known to exist but unexpected)
 - ▶ 3. the PDR defines a “common” side effect as occurring in 1% or more

So, if we want to MINIMIZE side effects, we’ve got to know why our patients get side effects in the first place:

Therefore, it is worth “one slide’s worth” of our time and attention to ask the fundamental question, “what exactly are “side effects” and why do we get “side effects” in the first place [pause here and ask the audience for some plausible explanations and discussion];

Bullet #1: indeed, if pharmaceuticals had perfect specificity there would be no side effects; let’s reconvene in around 10 years from now and we may find that big pharma has developed drugs that directly target that “third messenger” and turn on or off specific protein synthesis to get a perfectly specific intended effect with no side effects whatsoever.

Until then, the difference between a drug’s “intended effect” and its “side effects” is rather like the difference between a flower and a weed: if you like it, it’s called a flower, if you don’t like it, it’s called a weed.

Bullet #2: consider the well-known “anticholinergic profile” of many psychotropic

medications, including notably the FGA's, the TCA's, and some SSRI's.

Bullet #4: e.g., Lamictal & Stevens-Johnson syndrome

Bullet #6: CYP 450 enzyme induction


Bullet #7: e.g., "had gastroenteritis during the study"

Rule # 998: anyone can get any side effect to any medication

IOW: there have been Zillions and Zillions of medication s/e's and therefore even atypical s/e's are sometimes seen.

Key concept: difference between "side effects" (common, expected) vs. "allergic" (rare, unexpected)

Pop quiz




- ▶ You've diagnosed your patient with acute mania and immediately placed him on Depakote 1,000 mg TID. Within 48 hours he complains of acute GI upset, diarrhea, and hair falling out. The best explanation for this is:
- A. Patient is allergic to Depakote
 - B. Dose-dependent side effects
 - C. Psychosomatic reaction in a delusional, manic patient
 - D. You don't know your psychopharmacology & you prescribed the wrong drug
 - E. You prescribed the right drug, but you failed to start at low doses & titrate upward

Answer: E

Anticholinergic Side Effect Profile

- ▶ Blurry vision
- ▶ Dry mouth
- ▶ Constipation
- ▶ Urinary hesitancy
- ▶ Memory loss (elderly)
- ▶ Exacerbation of BPH, Glaucoma
- ▶ (rarely) hallucinations or delirium
- ▶ Mild tachycardia



So that's some fundamentals about side effects in general; one of the most important specific psychotropic side effects to know about is the so-called "anticholinergic side effect profile".

Elderly with less cognitive reserve = "CAS" or Central Anticholinergic Syndrome, severe memory loss and/or delirium


Anticholinergic s/e profile most commonly seen in:

FGA's

TCA's

some SSRI's

Serotonin pathways in the Brain




The serotonin pathways in the brain don't so much have discrete names as to the DA tracts, because Serotonin neurons project widely throughout the cerebral cortex and subcortically. 5HT pathways originate in the "dorsal raphe nuclei" deep in the brainstem and medulla and project both rostrally (upward into the brain) and caudally (toward the tailbone – down the spinal cord). Accordingly, serotonin – which is only transmitted or received by a paltry 1 to 2 % of all neurons – has widespread effects including:

- Mood
 - Anxiety
 - Blood pressure
 - GI function
 - Sleep
 - Appetite
 - Impulsivity
 - Obsessive-compulsiveness
 - Sexual function
 - Social dominance and/or social pain
-
- 5HT synthesized in brain and gut (80 – 90 % in gut).

The “DOMAINS” of Serotonin


- ▶ D Depression e.g., **Fluoxetine**
- ▶ O Obsessions (OCD) e.g., **Clomipramine**
- ▶ M Migraines e.g., **Sumatriptan**
- ▶ A Anxiety e.g., **Busprone**
- ▶ A Appetite e.g., **Fenfluramine**
- ▶ I Intestines e.g., **Ondansetron**
- ▶ N Nausea e.g., **Ondansetron**
- ▶ N Neuropathic pain e.g., **Meperidine**
- ▶ S Sexual functioning e.g., **Flibanserin**
- ▶ S Sleep e.g., **Melatonin**



The “DOMAINS” of Serotonin

- | | | |
|-----|--------------------|-----------------------------|
| ▶ D | Depression | e.g., Fluoxetine |
| ▶ O | Obsessions (OCD) | e.g., Fluvoxamine |
| ▶ M | Migraines | e.g., Sumatriptan |
| ▶ A | Anxiety | e.g., Sertraline |
| ▶ A | Appetite | e.g., Fenfluramine |
| ▶ I | Intestines | e.g., Ondansetron |
| ▶ N | Nausea | e.g., Ondansetron |
| ▶ N | Neuropathic pain | e.g., Meperidine |
| ▶ S | Sexual functioning | e.g., Cyproheptadine |
| ▶ S | Sleep | e.g., Melatonin |

Synthesis and degradation of serotonin



Smith *et al.* (1997)

Ondansetron = Zofran

- 5HT-3 antagonist
- Anti-emetic


Fenfluramine

- Promotes release of 5HT from pre-synaptic vesicles
- Weight loss drug withdrawn from market b/c of risk of pulmonary hypertension

Meperidine

- Demerol, an opiate analgesic
- Serotonin reuptake blockade
- Libby Zion at NYU hospital – on Phelzine for depression, maybe serorontin syndrome, got a shot of Meperidine from tired resident physician


GABA & Glutamate



- ▶ **Glutamate and GABA: A System in Balance**
- ▶ Glutamate and GABA (gamma-aminobutyric acid) are the brain's most plentiful neurotransmitters. Over half of all brain synapses use glutamate, and 30-40% use GABA.
- ▶ Since GABA is inhibitory and glutamate is excitatory, both neurotransmitters work together to control many processes, including the brain's overall level of excitation. Many of the drugs of abuse change the balance of glutamate or GABA, exerting tranquilizing or stimulating effects on the brain. Drugs that increase GABA or decrease glutamate are depressants. Those that decrease GABA or increase glutamate are tranquilizers or stimulants.
- ▶ Alcohol decreases glutamate activity.
- ▶ PCP, or "angel dust," increases glutamate activity.
- ▶ Caffeine increases glutamate activity and inhibits GABA release.
- ▶ Alcohol increases GABA activity.
- ▶ Tranquilizers increase GABA activity.

Our friend the Synapse

"You are your synapses. They are who you are."
— Joseph LeDoux, 2002 (in *Synaptic Self*)



- ▶ Synthesis of NT's in the neuronal cell body
- ▶ The fate of NT's at or near the synapse:
 - ▶ Transport & Release
 - ▶ Neurotransmission
 - ▶ Re-uptake
 - ▶ Metabolism
 - ▶ Blockade

Examples of each:

Synthesis: synthesis, or manufacture, of NT's depends on "rate-limiting" steps such as presence of co-factors (folate, methylfolate, MTHFR, etc.) and transcription signals within the neuronal cell nucleus (why consuming more tryptophan-rich foods doesn't cure depression: lack of tryptophan is not usually a "rate-limiting step" in biogenic amine synthesis).

Release: methamphetamine directly promotes release of DA & NT into the synaptic cleft


Transmission: successful binding of the NT to the receptor complex protein (results in: ion channel changes, action potential and/or intracellular second messenger release)

Re-uptake: NT resorbed back into pre- or post- synaptic neuron for recycling (note on the acronym "SSRI": SSRI's "inhibit" re-uptake of Serotonin)

Metabolism: NT is "digested" in the synapse by enzymes (predominantly COMT; COMT is blocked by MAO-I's)

Blockade: a competing molecule with greater binding affinity sits on the (pre- or post-synaptic) receptor complex, with either agonistic, antagonistic, or partial agonistic activity (Thorazine = post-synaptic blockade [“competitive antagonism”], [“nerve gas” = non-competitive agonism at post-synaptic, cholinergic receptors], antagonism of an antagonistic receptor (clonidine is an agonist at pre-synaptic [inhibitory] alpha-adrenergic receptors), or partial agonists (Buprenorphine is a “partial agonist”

Synapse: electron microscopy



Second Messenger System

Copyright © The McGraw-Hill Companies, Inc. Permission is required for reproduction or display.




Figure 3.9

3-19

CYCLIC AMP

- cAMP is a second messenger that is synthesized from ATP by the action of the enzyme **adenylyl cyclase**.
- Binding of the hormone to its receptor activates a **G protein** which, in turn, activates adenylyl cyclase.
- Leads to appropriate response in the cell by either (or both):
 - using **Protein Kinase A (PKA)** — a cAMP-dependent protein kinase that phosphorylates target proteins;
 - cAMP binds to a protein called **CREB (cAMP response element binding protein)**, and the resultant complex controls transcription of genes.
- Eg. of cAMP action - adrenaline, glucagon, LH

Explain:

First messengers (neurotransmitters)

Second Messengers (intracellular compounds like ATP/cAMP)

Third messengers

Disorders of the receptor compound:

- (1) genetic variants
- (2) autoimmune encephalopathies
- (3) nutritional deficiencies (hypocholesterolemia)

Save Our Synapses: dietary sources of key micronutrients

Folate:

- Lentils, beans
- Spinach, broccoli
- Avocado
- Oranges, mango

B-12 (cobalamin)

- Fish
- Meat, poultry
- Eggs, milk
- Not in plants

Zinc

- Meat
- Shellfish
- Legumes (chick peas, lentils)
- nuts

Magnesium

- Whole wheat
- Spinach
- Almonds, cashews
- Dark chocolate
- Yogurt, edamame

Vitamin D

- Salmon
- Cheese, dairy
- Fortified foods
- eggs

PUFA's

- Salmon, tuna, sardines
- Flax seed
- Walnuts
- soybeans

CoEnzyme-Q10

- Beef
- Pork, chicken
- Tuna, mackerel
- Cauliflower, broccoli, spinach

Calcium

- Milk, cheese
- Fortified O.J.
- Spinach, kale
- Collard greens
- Baked beans

Antioxidant-rich Foods

- Coffee, blueberries, dark chocolate, sweet potatoes, red grapes, tea, beans, fish

We've been talking about methyl donors such as folate and B-12, which are essential for biogenic amine synthesis (DA, NE, 5HT), so let's take a moment to remind ourselves of where some of these key nutrients come from in our diet ...

Grapes: anthocyanins, polyphenols, selenium

Blueberries:

Coffee, tea: catechins,

Dark chocolate:

Sweet potatoes:

Beans:

Dark leafy vegetables:

Nuts:

Serotonin Syndrome



CAN you diagnosis serotonin syndrome?

C	COGNITIVE CHANGES: Agitation, confusion, euphoria, insomnia, hypomania, hallucinations
A	AUTONOMIC CHANGES: Tachycardia, HTN, fever, diaphoresis, mydriasis, arrhythmias, tachypnea
N	NEUROMUSCULAR CHANGES: Tremor, hyperreflexia, clonus, ataxia, incoordination, seizures

Table 1. Drugs That Have the Potential to Cause SS

SSRIs Citalopram Fluoxetine Fluvoxamine Olanzapine/fluoxetine Paroxetine	Miscellaneous Buspirone Carbamazepine Cocaine Cyclobenzaprine Dextromethorphan Ergot alkaloids Fentanyl 5-Hydroxytryptophan Linezolid Lithium L-Tryptophan Meperidine Methadone Methamphetamine Methylene blue Metoclopramide Mirtazapine Ondansetron Phenelzine Selegiline St. John's wort Tramadol Tranylopramine Trazodone Tricyclic antidepressants Valproic acid
SNRIs Duloxetine Sibutramine Venlafaxine	
Triptans Almotriptan Eletriptan Frovatriptan Naratriptan Rizatriptan Sumatriptan Zolmitriptan	

SNRI: serotonin norepinephrine reuptake inhibitor; SS: serotonin syndrome; SSRI: selective serotonin reuptake inhibitor.
Source: References 6-13.

Maybe a more transparent name would simply be “Serotonin Toxicity”, but it’s “Serotonin Syndrome” and we’re stuck with it.

How about the acronym “CANT”, where the “T” stands for “taking a serotonergic medication” as part of the criteria?


Quite often, the result of taking multiple medications with 5HT-enhancing properties (less common, from one, high-dose medication): e.g., SSRI + migraine medicine (tryptan); SSRI + trazodone or meperidine; SSRI + tricyclic antidepressant (sometimes given as HS sleeping pill), SSRI + another SSRI or SNRI or Lithium; reportedly, SSRI + St. John’s Wort.

Overall, there’s no specific treatment for serotonin syndrome; stop taking the medicine that’s supplying the serotonin and offer supportive measures to bring down the fever and calm the fevered mind. Remember, pretty much the SSRI’s are wonderfully non-lethal even in massive overdose. The tricyclic antidepressants, that are quite lethal in overdose, kill people by virtue of causing cardiac arrhythmias, not by an overabundance of serotonin in the brain.

Maybe Cyproheptadine (Periactin) 12 mg orally, an antihistamine with 5HT antagonism properties. Cyproheptadine / Periactin has also been used to treat SSRI-induced sexual dysfunction.


Other NT systems of significance

- ▶ GABA
- ▶ Glutamate
- ▶ Oxytocin
- ▶ Acetyl Choline
- ▶ Adenosine
- ▶ Endocannabinoid
- ▶ Orexin



Antidepressant discontinuation Syndrome

- ▶ “Discontinuation” vs. “withdrawal”
- ▶ Usually mild
- ▶ Lasts from 1 day to 3 weeks (average of a week to 10 days)
- ▶ Risk factors:
 - ▶ Feeling better – go off meds
 - ▶ Become pregnant – go off meds suddenly
- ▶ Symptom cluster: next slide



“Discontinuation” vs. “Withdrawal”: separates AD’s from drugs of abuse (no “cravings”, no search for highs, no addictive properties). S. you “withdraw” from heroin, you “discontinue” Paxil.

Antidepressant discontinuation Syndrome

- ▶ **Sensory Symptoms**
 - ▶ Paresthesias
 - ▶ Numbness
 - ▶ Shock-like sensations
 - ▶ Visual trails (Palinopsia)
 - ▶ Rushing noise in head
- ▶ **Disequilibrium**
 - ▶ Light-headedness
 - ▶ Dizziness
 - ▶ Vertigo
- ▶ **Affective symptoms**
 - ▶ Irritability, anxiety
 - ▶ tearfulness
- ▶ **General somatic symptoms**
 - ▶ Lethargy
 - ▶ Headache
 - ▶ Tremor
 - ▶ Sweating
 - ▶ Anorexia
 - ▶ "Flu-like" symptoms
- ▶ **GI symptoms**
 - ▶ Nausea, vomiting
 - ▶ Diarrhea
- ▶ **Sleep disturbance**
 - ▶ Insomnia
 - ▶ Nightmares, increased dreaming

Six groups of symptoms

Some Sx look like depression itself, others are somewhat unique ("shock-like sensations", "brain zaps"); suspect AD Discontinuation Syndrome by history and timing

Antidepressant discontinuation Syndrome

▶ **DDX:**

- ▶ depressive relapse,
- ▶ Serotonin syndrome
- ▶ flu

▶ **Tx considerations:**

- ▶ Patient education
- ▶ Fluoxetine: requires no taper
- ▶ Reassurance
- ▶ Restart & change to a slow taper

Antidepressant discontinuation symptoms

- F = flu like symptoms
- I = insomnia
- N = nausea
- I = imbalance
- S = sensory disturbances
- H = hyperarousal (anxiety) (Gelenberg, 1998 cited in Carson, 2008, p. 432)

Metabolic Syndrome

- ▶ Includes high blood pressure, high blood sugar, excess visceral body fat (around the waist), & high cholesterol. Increased risk for heart attack and stroke.
- ▶ Aside from large waist circumference, criteria for metabolic syndrome have no symptoms.
- ▶ Risk Factors include: stress, sedentary lifestyle, pro-inflammatory state (TNF-alpha), diet, sleep deprivation, psychiatric illness, psychotropic meds
- ▶ Weight loss, exercise, healthy diet, smoking cessation can help. Medications may also be prescribed.



This is what a BMI of 53 will get you.


The great bugaboo of 1st generation antipsychotics was Tardive Dyskinesia: irreversible, disfiguring, disabling, virtually untreatable until recently.

2nd Gen. antipsychotics carry a vastly reduced risk for TD, but there is a new bugaboo: Metabolic Syndrome. Hypertension, hyperglycemia, dyslipidemia, hypercholesterolemia, and truncal obesity. Fats and sugars out of whack. All leading up to a high risk for vascular disease resulting in MI and CVA.

[Read slide]

Interestingly, obesity without metabolic syndrome does not significantly increase risk of heart disease, stroke, or T2D.

Metabolic Syndrome



FIVE FEATURES OF METABOLIC SYNDROME
Current criteria define metabolic syndrome as the presence of any three of the following traits:

- 1 **Abdominal obesity:** defined as a waist circumference in men of more than 40 inches and in women of more than 35 inches
- 2 **Serum triglycerides:** 150 mg/dL or drug treatment for elevated triglycerides
- 3 **Serum HDL cholesterol:** under 40 mg/dL in men and under 50 mg/dL in women or drug treatment for low HDL-C
- 4 **Blood pressure:** 130/85 mmHg or drug treatment for elevated blood pressure
- 5 **Fasting plasma glucose:** 100 mg/dL or drug treatment for elevated blood glucose

Metabolic Syndrome

- ▶ SGA's most associated:
 - ▶ Clozapine (Clozaril),
 - ▶ Olanzapine (Zyprexa).
- ▶ Middling association with metabolic syndrome:
 - ▶ Risperidone (Risperdal)
 - ▶ Paliperidone (Invega)
 - ▶ Quetiapine (Seroquel)
- ▶ Lower risk of metabolic syndrome:
 - ▶ Ziprasidone (Geodon)
 - ▶ Aripiprazole (Abilify)
 - ▶ Lurasidone (Latuda)



Always provide monitoring of metabolic parameters, nutritional recommendations, prescribe exercise and physical activity as part of prescribing antipsychotic medication.


Be willing to switch medications if signs of weight gain or metabolic syndrome appear.

Many psychiatric patients are already taking statins to lower cholesterol and anti-hypertensives for blood pressure; sometimes the SGA can't be lowered due to risk of hospitalization but a statin can be added.

This slide lists SGA's only; all the FGA's (Haldol, Thorazine) have a lower incidence of metabolic syndrome than the SGA's.

Neuroleptic Malignant Syndrome

- ▶ Rare but life-threatening complication of Antipsychotic meds
- ▶ Largely occurs with 1st or 2nd week of Tx
- ▶ Patients will "Shake" –
 - ▶ Severe muscular rigidity
 - ▶ Hyperthermia
 - ▶ Autonomic overactivity (BP, diaphoresis)
 - ▶ Changes in Kconsciousness
 - ▶ Exposed to Neuroleptics recently
- ▶ Oral meds: days, IM meds: weeks
- ▶ Tx: fluids, bromocriptine or Dantrolene



Severe Muscular rigidity: “lead pipe” rigidity, shuffling gait, trouble swallowing

Changes in consciousness: delirium, confusion, stupor

Lab findings variable but more often than not include elevated CPK (muscle breakdown), Leukocytosis (white blood cells), decreased O2 on oximetry.

Supportive care includes admit to hospital ICU: fluids, anti-pyretics, O2, benzodiazepines, and DA-agonists for severe cases (Bromocriptine, Dantrilene).

DDx: Serotonin Syndrome, Malignant Hyperthermia, Lethal Catonia, Amphetamine psychosis, aseptic meningitis

AMS = “Altered Mental Status”

Stevens-Johnson Syndrome

- ▶ Severe, potentially fatal exfoliating dermatitis
- ▶ Can affect skin, lips, mouth, eyes, genitals
- ▶ Often drug-induced including one common psychotropic, **Lamotrigine (Lamictal)**
- ▶ Inform patient of risk, tell them to get to ER, stop taking the medicine at any sign of a deep or extensive or rapidly spreading rash
- ▶ Admit to ICU and burn unit




Khaliah Shaw, University of Georgia student

Part 2: Prescribing psychotropic medication

PRINCIPLES OF PRESCRIBING

PHARMACOKINETIC CONCEPTS YOU REALLY NEED TO KNOW ABOUT



Okay, so in Part 1 we looked at brain regions, brain functions, and the neurotransmitters associated with those regions and functions. We developed an understanding of how “side effects” and “intended effects” are simply different aspects of the overall range of effects of any given drug, subjectively viewed like the difference between a “flower” and a “weed”, and considered 4 major syndromes associated with psychotropic prescribing:

AD discontinuation syndrome

Serotonin syndrome

Neuroleptic Malignant syndrome, &

Metabolic syndrome

Principles of prescribing psychotropic medications:

- ▶ Efficacy vs. tolerability
- ▶ Intended effects vs. side effects, & the skillful leveraging side effects
- ▶ Patient preferences & sensitivities
- ▶ Medication history, notable past medication successes or failures
- ▶ Family medication history ("my sister and mom take Paxil")
- ▶ Medical problems, thyroid symptoms
- ▶ Liver or kidney problems: may choose meds with renal vs. hepatic metabolism
- ▶ Exercise status, need for alertness
- ▶ Suicide risk: generally choose meds that are potentially less lethal
- ▶ Patient's attitude toward taking psychiatric medication
- ▶ Patient's motivation and ability for scrupulous daily adherence
- ▶ Drug or alcohol intake while taking medications
- ▶ Generally avoiding meds with abuse potential or discontinuation problems
- ▶ Relative importance of the "medication piece" in the overall treatment plan
- ▶ Nutritional patterns (Vit D, folate, fats, pro-inflammatory vs. anti-inflammatory diet, anti-oxidant intake)
- ▶ Degree of diagnostic certainty
- ▶ Rational vs. random polypharmacy

"patient preferences & sensitivities" e.g., sexual dysfunction may be a very important concern for some patients but not for others; likewise for weight gain, acne, cardiac risks.

As we move along, we'll see examples of specific medications within each class have specific side effects that can be either helpful, neutral, or annoying and harmful for specific patients.

Pop Quiz

Essential Considerations before prescribing a psychotropic include all EXCEPT:

- ▶ A. establish the diagnosis by history and examination
- ▶ B. identify any comorbidities such substance abuse
- ▶ C. gain the allegiance and cooperation of the patient in the proposed treatment plan
- ▶ D. have a discussion of target symptoms, precautions, and possible side effects
- ▶ E. skillfully leverage likely side effects to therapeutic advantage
- ▶ F. be sure to discuss psychotherapy as well as medication treatment
- ▶ G. assess for suicide risk
- ▶ H. verify insurance coverage



Answer A: the absolute minimum, also gets at the concept of “are we treating symptoms, or are we treating the underlying diagnosis?”

Answer C: important for (a) having realistic expectations, (b) ensuring compliance with taking the medicine every day.

Answer D: ask the patient “of all the symptoms you’ve mentioned, not sleeping, low motivation, feeling sad all the time, panic attacks, what’s most important that we try to take care of first?”

Answer E: i.e., the “kill two birds with one stone” principle: e.g., patient is depressed and sleepless: using an antidepressant that commonly includes sedation as a possible side effect, to be taken at bedtime. Or, E.g., patient has some ADHD symptoms and Wellbutrin or Trintillex makes sense.

Answer F: gets at the common problems of patients with dysfunctional core beliefs (& maladaptive, reflexive coping mechanisms), who remain “partial non-responders” ...

Correct answer: H


Common medical causes of psychiatric symptoms

- ▶ **Endocrine**
 - ▶ Hypothyroid
 - ▶ Hyperthyroid
 - ▶ Cushing's disease
 - ▶ Cushing's syndrome
 - ▶ Pheochromocytoma
- ▶ **Tumor**
 - ▶ Pituitary adenoma
 - ▶ Pancreatic cancer
- ▶ **Medications**
 - ▶ BP meds
 - ▶ psychotropics
- ▶ **Metabolic**
 - ▶ Low potassium, sodium, folate, B12, Mg, vitamin D, cholesterol
- ▶ **Toxins, infections**
 - ▶ Lead, mercury, manganese, arsenic
 - ▶ CO poisoning
 - ▶ Volatile solvents
 - ▶ Lyme disease

Thyroid symptoms: cold/heat intolerance, weakness, oedema, hair loss or trophic changes, amenorrhea, vital signs, constipation or hyperdefecation, lid lag or exophthalmos

Overall, look for (and ask for) ANY unexplained symptom, especially if asymmetrical, visible, or measurable.

Cushing's d.




Cushing's syndrome (also called hypercortisolism) – not always easy to diagnose (patient complains of fatigue, depression, weakness, weight gain, and headache)

- Very common: 3 million cases a year in the USA
- Cushing's syndrome: too much exogenous steroid
- Cushing's disease: adrenal gland disease, too much cortisol production
- Characteristic signs and symptoms: truncal obesity and extremity wasting ("lemon on toothpicks")
- Pigmented striae (pink or purple stretch marks), thinning and easy bruising of the skin
- Fat pad ("buffalo hump") and rounded face ("moon facies")
- High blood pressure, osteopenia, and hyperglycemia

- Acne, depression, fatigue, muscle weakness, decreased libido
- High dose steroids used for inflammatory conditions such as rheumatoid arthritis, lupus, asthma, transplant immunosuppression, etc.
- Endogenous: pituitary adenoma (with excessive ACTH secretion), exogenous ACTH-secreting tumor, or primary adrenal cortical tumor

hypothyroidism




Hypothyroidism (underactive thyroid gland, too little thyroid hormone produced)

- 10 to 15 million cases per year; contrast to 135,000 new cases of colon cancer per year in US
- More common in women than men
- Fatigue, constipation, edema, weight gain, constipation, amenorrhea
- Characteristic “trophic changes” – hair and skin – , peripheral edema & peripheral neuropathy
- Bradycardia and hypothermia
- Causes: tumor, autoimmune disease, iodine deficiency, medication (lithium), pituitary tumor (low TSH)

Pharmacokinetics (how a drug behaves in the human body)

- ▶ Absorption
 - ▶ Distribution
 - ▶ Metabolism
 - ▶ Excretion
- ▶ Just remember the phrase:
- ▶ "AD ME"



Examples of significant impact:

Absorption: rate of absorption determines whether the patient experiences a rush or "high" from the medicine: e.g., Alprazolam (Xanax) vs. Lorazepam (Ativan).

Distribution:

Absorption

- ▶ A tale of two drugs with the same half-life but different rates of absorption




Figure 4. Mean steady-state alprazolam plasma concentrations in 17 volunteers after administration of 6 mg/d alprazolam-CT (qid) and alprazolam-XR (bid) tablets. Source: The Upjohn Company, Kalamazoo, Mich. Data on file, Technical Report No. 7215-91-022.

Distribution

- ▶ **Lithium** distributes in the water compartments of the body
- ▶ When dehydrated, lithium level can go up – even to a toxic level
- ▶ **Propranolol** is a lipophilic beta-blocker and can cause CNS side effects such as "beta blocker blues"
- ▶ **Atenolol** is a hydrophilic beta-blocker and doesn't penetrate the BBB
- ▶ **Zoloff** does not distribute to breast milk in lactating mothers
- ▶ **Paxil**, another SSRI drug of the same class as Zoloff, does

Lithium Pharmacokinetics

Lithium Pharmacokinetic Parameters

Absorption
Dosage form (Tmax)
Liquid (.25-1)
Cap. tab (.5-3)
Sustained release (2-6)
Bioavailability 80-100%
Volume of distribution: 7-1.0 L/kg
Metabolism, not metabolized, renal elimination
Elimination
Clearance 10-40 mL/min
Half-life 18-36 hr

J Clin Pharmacol 1984;34:280-285.


Brand names:

Propranolol = Inderal

Atenolol = Tenormin

Metabolism

- ▶ **Vyvanse (Lisdexamfetamine)** = Lysine + Dextroamphetamine
 - ▶ An "inactive pro-drug"
 - ▶ Undergoes "enzymatic cleavage" separating the lysine from the amphetamine
 - ▶ This occurs during "first pass" metabolism
 - ▶ No chance of diversion for snorting or injecting
-
- ▶ **Prozac (Fluoxetine)**
 - ▶ "biotransformation" to an "active metabolite" with a humongously long half-life



The idea of "First Pass" metabolism = the hepatic metabolism that occurs BEFORE your body uses the drug, not afterward ...

Fluoxetine $T_{1/2}$ = 2 to 4 days

Norfluoxetine $T_{1/2}$ = 7 to 15 days

Practical implication: drugs with longer half-lives have to be managed differently:

- (1) e.g., when switching antidepressants, can have serotonin syndrome with Prozac
- (2) E.g., when switching to an MAO-I, must have longer washout period with Prozac
- (3) E.g., "self-taper" lowers risks of AD-discontinuation syndrome, non-compliance
- (4) "drug holiday" strategy for Tx of SSRI-induced sexual dysfunction works with Paxil but not Prozac

Drug-Drug Interactions: Inducers & Inhibitors

Drug Interactions (Liver)

Induction and Inhibition

- Metabolism based drug-drug and other interactions can have a significant influence on the use and safety of many drugs.
- Induction of drug metabolism can lead to unexpected drops in drug concentration or the build-up of metabolites. The reverse can occur when there is inhibition of drug metabolism.
- The major organ involved in metabolism is liver and the major enzyme system involved in drug metabolism is CYP 450, the well-known family of oxidative hemo-proteins. Induction CYP 450 enzymes at the liver is responsible for induction of metabolism of many drugs.

Hepatic enzyme induction is like when you're at the inveterately slow check-out lines at Giant or CVS, when, miraculously, it's your luck day and the manager opens up another register, increasing the rate at which customers can check out and leave the store; the liver increases the rate of metabolism of a drug by increasing production of the enzymes that metabolize the drug. The result is analogous: fewer customers standing in line at CVS, and a lower serum level of the drug in the bloodstream.

Examples: nicotine = inducer (stop smoking, can get toxic & have seizures w/ Clozapine)

St. John's Wort (*hypericum perforatum*) = inducer (w/OCP's, can become pregnant)

Carbamezapine (Tegretol) = inhibitor

Grapefruit juice = inhibitor

Induction/inhibition is not the only mechanism for side effects, for example combined,

similar actions of different drugs can result in S/E's: e.g., Celexa for depression + Trazodone for sleep = too much Serotonin & could – in theory – result in Serotonin Syndrome.

memorized.

Induction/inhibition is not the only mechanism for side effects, for example combined, similar actions of different drugs can result in S/E's: e.g., Celexa for depression + Trazodone for sleep = too much Serotonin & could – in theory – result in Serotonin Syndrome. Or, Lithium, a salt, is treated a lot like Sodium by the body; drugs like diuretics that lower blood pressure by causing the body to lower fluid volume and lose salt also can increase lithium excretion and lower lithium levels.

Genetic variability also plays a big role, as some individuals are genetic “slow metabolizers” for the P450 system.

Excretion

- ▶ Depakote = hepatic/enteral
- ▶ Lithium = renal
- ▶ Lamictal = hepatic/enteral
- ▶ Neurontin = renal

Half-Life is an important factor in Excretion


- **Half-life:** The period of time required for the concentration or amount of drug in the body to be reduced by one-half
 - **4-5 X half-life=Steady State**
 - As repeated doses of a drug are administered its plasma concentration builds up and reaches what is known as a steady state. This is when the amount of drug in the plasma has built up to a concentration level that is therapeutically effective and as long as regular doses are administered to balance the amount of drug being cleared the drug will continue to be active. The time taken to reach the steady state is about five times the half life of a drug.
- Steady State does not = onset of drug action


So in treating bipolar disorder, your drug of choice decision may be influenced by the patient's liver or kidney status. If the patient has cirrhosis or another hepatic disease, you might choose drugs handled by the kidneys. Conversely, your patient has renal impairment, you'd be inclined to choose drugs that go the route of hepatic metabolism.

There's the same choice to make in MAT for alcohol abuse: Naltrexone is hepatically metabolized, and conversely Acamprosate (Campral) is renally excreted.

Matching: draw a line to connect the two matching phrases

- | | |
|--|--|
| (1) How long the effect of a drug lasts in a person | (A) Half-life |
| (2) Precisely what the drug does in the body in order to exert its effect on a person | (B) Mechanism of Action |
| (3) How long it takes the body to reduce the amount of drug by $\frac{1}{2}$ | (C) Therapeutic Index |
| (4) The ratio between the amount of drug needed to cure and the amount needed to kill a person | (D) Active metabolite |
| (5) Lipophilicity | (E) Duration of action |
| (6) A compound not ingested by the person that has a therapeutic effect nonetheless | (F) A proxy for how likely it is that a drug will enter the brain or not |





Part 3: psychopharmacology today

MEDICATIONS GROUPED BY CLASS

SOMETHING INTERESTING OR UNIQUE ABOUT ALMOST EVERY ONE

Okay, so in part 2 we looked at the rules and concepts prescribers use when prescribing, we considered some common medical illness that masquerades as psychiatric illness, and we got introduced to the very important field of pharmacokinetics, specifically how knowledge of absorption, distribution, metabolism, and excretion, or “AD ME” informs skillful psychotropic prescribing.

The classes of psychotropics:


- ▶ Antidepressants
- ▶ Anti-anxiety agents
- ▶ Antipsychotics
- ▶ Mood stabilizers
- ▶ Sleeping agents
- ▶ Dementia medicines
- ▶ Medication treatments for addictions
- ▶ ADHD medications

TCA Antidepressants

- ▶ Among the oldest AD drugs
- ▶ Tertiary amines
 - ▶ Amitriptyline (Elavil)
 - ▶ Imipramine (Tofranil)
 - ▶ Trimipramine (?)
 - ▶ Serotonergic, noradrenergic, & anticholinergic, histaminergic
- ▶ Secondary amines:
 - ▶ Nortriptyline (Pamelor)
 - ▶ Desipramine (Norpramin)
 - ▶ Protryptiline (?)
- ▶ Efficacy as compared of SSRI's
- ▶ Fatal in O/D
- ▶ cardiac arrhythmias

TRICYCLIC ANTIDEPRESSANTS (TCAs)

- The first tricyclic antidepressant discovered was **Imipramine**, which was discovered accidentally in a search for a new antipsychotic in the late 1950s.
- Imipramine hydrochloride is a member of the dibenzazepine group of compounds. It is designated 5-[3-(Dimethylamino)propyl]-10,11-dihydro-5H-dibenz[*b*,1-*a*]azepine] Monohydrochloride.



Imipramine (Tofranil)

AMI is metabolized to NT

IMI is metabolized to DES

An interesting fact is that AMI is one of the most anticholinergic (think: lots of side effects) antidepressants, while NT is one of the LEAST anticholinergic antidepressants.

There are also related compounds known as “tetracyclic” antidepressants (maprotiline, amoxapine) just for the record, but we don’t need to go into those for today’s purposes. OR: amoxapine was thought to act as BOTH an AD and anti-psychoticAmoxapine wonderful brand name: Asendin.

Some Danish studies suggested that TCA’s are more effective than SSRI’s, and if you’re hospitalized for severe depression non-responsive to SSRI’s, you’re likely to get Rx’ed TCA’s.

Trimipramine = Surmontil; Protryptiline = Vivactil.


TCA's

Tricyclic Antidepressants: Adverse Effects

- Commonly reported AEs (generally anticholinergic):
 - blurred vision
 - cognitive changes
 - constipation
 - dry mouth
 - orthostatic hypotension
 - sedation
 - sexual dysfunction
 - tachycardia
 - urinary retention



- Desipramine
- Nortriptyline
- Imipramine
- Doxepin
- Amitriptyline



TCA's effective in depression, anxiety & panic attacks, OCD.

Another TCA: Chlorimipramine (Anafranil);

SSRI antidepressants

▶ Common SSRI's:

- ▶ **Fluoxetine/Prozac** – long half life
- ▶ **Paroxetine/Paxil** – discontinuation syndrome, weight gain, sexual dysfunction
- ▶ **Sertraline/Zoloft** – doesn't get into breast milk
- ▶ **Citalopram/Celexa** – anticholinergic s/e's
- ▶ **Escitalopram/Lexapro** – S-enantiomer of Celexa
- ▶ **Fluvoxamine/Luvox** – associated with OCD Rx

▶ Common SSRI Side effects:

- ▶ GI: nausea, cramps, diarrhea
- ▶ Sexual dysfunction
- ▶ Weight changes
- ▶ Drowsiness
- ▶ Restlessness, agitation
- ▶ Help you feel normal again, or emotional deadness inside
- ▶ Sweating, tremor
- ▶ Headache, or make headache go away

Well, the TCA's brought millions of people out of depression but there was a heavy price to be paid. Patients weren't happy with weight gain, sedation, "cotton mouth", blurred vision, orthostatic hypotension (fainting from low blood pressure when you stood up too quickly), and other TCA side effects, and doctors weren't happy being constantly distracted from their golf games by nagging thoughts that their depressed patients might at that very moment be taking a fatal overdose of their TCA medication, or developing serious cardiac arrhythmias. So, when the first of a new class of drugs, Fluoxetine or Prozac, came out as an "SSRI", essentially the modern era of psychopharmacology was ushered in. SSRI's are non-fatal in overdose. Prozac didn't yet exist when I was first prescribing antidepressants and I still remember being taught not to prescribe more than a total of "2 grams" of a TCA to a new patient. Because an average daily dose was up to 100 mg, and the TI put a potentially fatal overdose at 30 to 50 times the daily dose, "2 grams of Elavil" (or equivalent in Pamelor or Norpramin) was roughly 20 days' supply, but still well short of a potentially fatal concoction if the patient were to go suicidal and swallow their entire bottle of pills at once.

Nearly impossible to overdose on SSRI's – in stark contrast to TCA's. That made everyone happy: the doctors could make it to the 18th hole without worrying about a call from the ICU or their malpractice attorney, and the patients could take an

attention-getting overdose of their SSRI and not have to worry about a fatal miscalculation. As a result, Prozac and the other “me too” SSRI’s that quickly followed soon became more popular than a bitcoin offering at a NASDAQ convention. Patients rushed to their doctors crying “get me some Prozac”. Doctors rushed to their stock brokers crying “get me some Eli Lilly.” Everyone was happy. It was a good time to be alive.


SSRI’s are most commonly Rx’ed class of AD’s, but not really because they are more effective than the old-fashioned TCA’s, but – remembering the rule about considering both efficacy and tolerability – they were both safer and more tolerable than the TCA’s. Mostly, the SSRI’s have very little cardiovascular impact and that has made everyone more comfortable. I can recall occasional reports about sudden cardiac death in children prescribed TCA’s and we haven’t had to worry about that problem any more.

Prozac = longest half-life. Implications: good for patient who might miss a dose here or there; self-tapers therefore no discontinuation syndrome; bad if switching to another SSRI because it lingers in the system.

Citalopram vs. Escitalopram = Citalopram risk of QTc prolongation at 60 mg/day; therefore upper limit recommended at 40 mg daily; dose of Escitalopram half that of Citalopram.

The list of s/e’s is kind of crazy and sometimes I feel embarrassed to tell a patient “you may sleepy or you may get insomnia” ... “you may feel less depressed or you may feel suicidal” “Your sex drive may return or your sex drive may go down” so I say **“serotonin is a balance and either too much or too little can cause a problem”**

SSRI's



Do anti depressants work?

- **50-65%** of patients given an SSRI for three months showed signs of improvement in tests
- **HOWEVER** the other test group were given a **PLACEBO** (pretend drug) and this group showed a **25-30%** improvement

LOOKS LIKE THE PLACEBO HAS HELPED YOUR DEPRESSION!

GREAT! GIVE ME A DOUBLE DOSE NEXT TIME!


The safety profile of SSRI's became such that the threshold for writing a prescription went down. Previously, a patient had to be considered very seriously depressed before being put on a course of (TCA) antidepressants. A lot of time was spent trying to tease out whether the depression was "biological" or "psychological" before deciding to prescribe an antidepressant. After Prozac and the SSRI's, however, anyone who reported feeling depressed or perhaps, at times, even just a little "bummed out" was issued a prescription for Prozac. Peter Kramer wrote a book with the absolutely worst pun in the entire history of biological psychiatry called "Listening to Prozac" suggesting the drug was so potent that it could potentially remold personality which had been subtly misshaped by undiagnosed depression, and again the masses stampeded to their doctor's offices. The demand was so great that treating depression was no longer the domain of the psychiatrist but family practitioners, internists, and OB-GYN began doing the majority of antidepressant prescribing. Oh, by the way, Dr. Kramer's pun? He was smitten with the idea that "Prozac" sounded a lot like "Muzak" and thought the title would make everyone think of the phrase "Listening to Muzak". Nonetheless, patients began comparing their antidepressants over water cooler talk at the office and I can recall many patients saying, "my boss said he's on Paxil and I wonder if that would be better for me than my Zoloft, doc". The trend has not let up and nowadays 13% of the US population over the age of 12 – more than one

of every eight adults – is taking an antidepressant medication.

“Daily use of SSRIs for more than a week or two eventually results in changes in the structure of neurons. This is neuroplasticity, the brain's ability to reorganize its neural connections, in action. As neurons adapt to new levels of serotonin, they make adjustments in the number of receptors, grow new dendrites, or even promote the development of new connections or circuits.¹ In other words, new, higher levels of serotonin may somehow stimulate the neurons to remodel themselves and their circuits in a variety of ways, a process called neurogenesis.”

SNRI & other antidepressants


- ▶ **Venlafaxine (Effexor)**
 - ▶ Both 5HT and NE agonist
 - ▶ Less serotonin excess
- ▶ **Desvenlafaxine (Pristiq)**
- ▶ **Mirtazapine (Remeron)**
 - ▶ Add Bupropion for "California Rocket Fuel"
- ▶ **Duloxetine (Cymbalta)**
 - ▶ Short half-life
 - ▶ Approved for neuropathic pain
- ▶ **Vortioxetine (Trintillex)**
 - ▶ Aids cognition?
 - ▶ Low side effect profile?



Discuss prescribing an SNRI, vs. prescribing two separate meds, e.g., Zoloft + Wellbutrin (advantage of the former, is using one med vs. two; advantage of the latter is that you can start with the SSRI and if there's a partial response but side effects are creeping in, then you add the Wellbutrin rather than increase the SSRI and increase the dose-dependent side effects).

Antidepressant-induced hyponatremia

- ▶ About 1 in every 200 people
- ▶ Symptoms are non-specific so need a high index of suspicion
- ▶ Elderly are more at risk
- ▶ Can be fatal in up to 25% of elderly
- ▶ Often have other risk factors for hyponatremia
- ▶ Can be asymptomatic
- ▶ Among US athletes,
 - ▶ No deaths from dehydration
 - ▶ 15% rate of hyponatremia from excessive H₂O drinking
 - ▶ MD Alerts suggests deaths in marathoners assoc w/ low Na⁺



Drug-induced hyponatremia is also common and should not be overlooked. “Natrium” is Sodium, or “table salt.” (Sodium Chloride, or NaCl).

Hyponatremia is defined as having a serum sodium level of less than 134mmol/L. Most patients with mild hyponatremia are asymptomatic. However when the serum sodium level drop below 120mmol/L, the patient may start to experience headache, lethargy and nausea. In severe cases of hyponatremia, neurologic and gastrointestinal symptoms can occur with the risk of seizure and coma to increase rapidly as the sodium level continues to drop.

Every Year, More Athletes Are Injured By Hyponatremia than Dehydration

By John Henry Dreyfuss, MDAlert.com staff.


April 14, 2015 [EndocrinologySports Medicine](#)

MAO Inhibitors



MAO-I Antidepressants

- ▶ **Monoamine Oxidase (MAO)**
- ▶ Metabolizes, or breaks down, the monoamines (DA, NE, 5-HT) at the synapse
- ▶ MAO inhibitors block the action of MAO
- ▶ The result of this "enzyme inhibition" is less NT breakdown
- ▶ Therefore, more NT activity at the synapse
- ▶ Nardil, Parnate, Marplan, Eldepryl
- ▶ Also used in Parkinson's D to increase available Dopamine



MAO-I side effects are most commonly:

- Hypotension
- Weight gain
- Sedation

Less common but worrisome:

- Acute hypertensive crisis
- Tyramine/tyrosine build-up
- Avoid aged, pickled, fermented foods
- Includes cheeses and wine, some beer
- Chicken or tuna salad leftover in fridge, pizza, etc.

Rarely prescribed nowadays due to (1) common side effects, (2) risk of hypertensive crisis, (3) superior alternatives available, and (4) less commonly see "hysteroid dysphoria".

- Generic names: phenelzine, tranylcypromine, isocarboxycid, selegine

Atypical Antidepressants

- ▶ **Mirtazapine/Remeron**
 - ▶ Helps with insomnia
 - ▶ Risk of weight gain
- ▶ **Bupropion/Wellbutrin**
 - ▶ NE/DA only
 - ▶ Non-sedating
 - ▶ No weight gain
 - ▶ No sexual dysfunction
- ▶ **Trazodone/Desyrel**
 - ▶ Used for insomnia
 - ▶ Watch out for Priapism

Priapus, a minor, rustic, well-endowed fertility god:



Remeron: complex pharmacological mechanism of action, “NaSSA” – “NE and specific serotonin antidepressant” b/c hits a few specific 5HT sub-types.


Wellbutrin: think of Wellbutrin when

- (1) non-response to multiple SSRI's
- (2) Want to avoid SSRI-induced sexual dysfunction
- (3) Want to avoid weight gain or sedation as a side effect
- (4) Maybe some ADHD and you can kill two birds with one stone (“rational monotherapy” vs. “rational polypharmacy”)
- (5) Want to minimize risk of medication-induced hypomania
- (6) For a “poor-man’s contrive”
- (7) Have partial response to SSRI but getting limited by dose-dependent side effects

Trazodone: Ubiquitous, for sleep these days

Pop quiz

Matching:



Duloxetine: NE and 5HT blockade; indication for neuropathic pain thought to be due to Sodium ion channel blockade in the spinal cord

If you see a patient on duloxetine, suspect a medical condition such as diabetic neuropathy or fibromyalgia.

Natural Remedies for Depression

- ▶ **St. John's Wort**
 - ▶ Hypericum Perforatum (Hypericin)
 - ▶ Weakly serotonergic
 - ▶ Reduces cytokine production
 - ▶ Constipation, phototoxicity
 - ▶ Enzyme inducer of CYP3A4
- ▶ **SAMe**
 - ▶ S-Adenosyl Methionine
 - ▶ Co-factor in biogenic amine prod.
 - ▶ Helps in pts. With MTHFR deficiency
 - ▶ 2 to 3 gm/daily
- ▶ **Valerian root**
 - ▶ GABA-like effects
 - ▶ Good sedative, not so good anti-Depr.
- ▶ **Omega-3 Fatty Acids**
 - ▶ Long-chain polyunsaturated fatty acids
 - ▶ Chiefly DHA & EPA (fish oil) & ALA (flax seed)
 - ▶ MOA: stabilization of the neuronal cell membrane & anti-inflammatory effects
 - ▶ 30 RCT's, mixed EPA/DHA composition
 - ▶ May be helpful adjunct at 2 gm daily
- ▶ **Melatonin**
 - ▶ Manufactured in pineal gland
- ▶ **5HTP (5-hydroxytryptophan)**
 - ▶ Appealing due to 5HT hypothesis of depression, 5HTP is an intermediate compound in 5HT synth.
 - ▶ Eosinophilia-myalgia syndrome resulted in temp. ban
 - ▶ Efficacy uncertain

SJW: pretty yellow flower that blooms every year around St. John's Day. Probably the most well-studied of all the CAM therapies for depression. Evidence suggests it's about as effective for mild to moderate, but not severe, depression as TCA's or SSRI's at a dose of around 500 mg BID. Personally, I don't believe it b/c I've never seen anyone for whom it's worked, but then again, if it was working, they would need to visit a psychiatrist office, would they? Not without side effects, particularly constipation and photosensitivity reaction, with a lot of redness and peeling of the exposed skin. Can induce mania in bipolar patients.

Dozens of trials of **SAMe** vs. Rx antidepressants, generally mild side effects including loss of appetite, dry mouth; also possible to induce mania in bipolar patients. Some studies suggest efficacy in depression. Pricey, however. May be combined with standard antidepressants.

OFA's: At least one impressive study found DHA levels inversely correlated with risk of suicide. ALA from flax seed also very healthy but less psychoactive.

Other non-Rx & natural remedies:

Rhodiola Rosea – a plant that grows in Russia and Eurasia, more widely known there.

May have adaptogen & anti-oxidant properties, and some MAO-I properties. Taken from 100 to 600 mg daiy, few side effects, used for depression, anxiety, fatigue, stress, and sexual dysfunction.

5 Hydroxytryptophan: short half-life necessitates TID or QID dosing ($t_{1/2} = 4$ hours); usually 100 mg TID or QID, Gi side effects are possible (nausea, vomiting, diarrhea).

Valerian Root: used for over 1,000 yrs; carried in WWI medic bag; may have GABA-ergic properties; “natural substitute for benzo’s?”; 450 to 600 mg at HS; powerful smell prevents RCT b/c no placebo has a similar smell; overall, probably good for sleep but so-so for depression.

Melatonin: resets Circadian rhythm; a sleep-inducing hormone. Rx 1 to 5 mg at HS. Few side effects include confusion, sedation, nightmares; rarely infertility, lowered body temperature, and immunosuppression.


Gingko Biloba: cognitive enhancer for dementia, also being used for reversing SSRI-induced sexual dysfunction; functions to stabilize neuronal cell membrane and a free radical scavenger; some efficacy in slowing dementia and a lot of speculation as to whether taking it early can help prevent dementia. Can be combined with Cholinesterase Inhibitors (Aricept) for increased efficacy; possible side effect of worsening bleeding disorders so should not take if taking an anticoagulant.

Who prescribes psychotropics

Medication class	Psychiatrists (%)	Non-psychiatric MD's (%)
Antipsychotics	40	60
Antidepressants	15	85
Antianxiety	10	90
Hypnotics	11	89
Lithium	62	38

Pomerantz et. al. 2004. J Clin Psychiatry

Switching: STAR-D findings



With respect to “switching”, from the well-known STAR-D trials, intuitively you would imagine that if the patient has failed one SSRI, the last thing you’d want to do would be to switch to a second SSRI.

Well, switching to a second SSRI after a failed 1st SSRI was compared to switching to an SNRI, an “NDRI” (no serotonin augmentation), or an old, frumpy, antiquated TCA.

The result – counterintuitive: all were helpful, no differences in efficacy.


That goes for “what to switch to”; as for “how to make the switch” – i.e., an overlap? An underlap? A sudden switch? The answer lies in: pharmacokinetics! For almost all AD’s, you can just do a sudden, “all at once” switch.

But for Prozac, with Norfluoxetine and its Humongously long half-life, wait a week – otherwise you’re at risk from side effects of too much serotonin, or even Serotonin Syndrome.

The trouble with algorithms: every patient is an individual in terms of symptoms, severity, length of illness, comorbidities, & vulnerabilities.

STAR-D


- ▶ Large patient population (n = 4,000), year is 2006
- ▶ From both psychiatry and primary care clinic populations
- ▶ Minimal exclusionary criteria
 - ▶ (intended to capture "real world" patient populations)
- ▶ Treatment not blinded
- ▶ Patient preferences taken into account
- ▶ 4 "treatment levels"
- ▶ Move to next level if < 50% toward remission



For “extra credit”: What does STAR-D stand for?

“Sequential Treatment Alternatives to Relieve Depression”

STAR-D




Level 2 = 3 combo's + 4 switches for a total of 7 different options



“Non-remitters” go to level 3, or Level 2A

STAR-D

- ▶ Level 1: 47% response, 37% remission
- ▶ Level 2: No Significant differences between antidepressant choices
- ▶ Level 3 remission rates:
 - ▶ Remeron = 12%
 - ▶ Nortriptyline = 19%
 - ▶ Added Lithium = 16%
 - ▶ Added T3 = 25%
- ▶ Level 4: 13% remission rate for either option



STAR-D



So the beauty of STAR-D is the naturalistic conception of depression that minimizes exclusionary criteria and therefore maximizes the similarity to real-world patient populations. But as you can see, there's tremendous flexibility built into this algorithm with lots of choices within each of the four levels.

Some groups likely to non-respond or get worse on antidepressants

- ▶ **Bipolar patients**
 - ▶ More likely to see mixed Sx appear rather than AD-induced hypomania
- ▶ **MDD with mixed features**
 - ▶ Recommend: SGA's rather than AD's
- ▶ **Borderline PD**
 - ▶ Recommend: anti-convulsants or SGA's
 - ▶ Meds get wrapped into SIB dynamics
- ▶ **Younger age**
 - ▶ Less efficacy
 - ▶ Higher para-suicidality
- ▶ **Genetic variants**
 - ▶ Short-Short 5HT transporter gene
 - ▶ Slow-metabolizers have higher blood levels and see side effects before therapeutic effects



Portrait of a non-responder

Partial responders things to think about (slide 1)

- ▶ Rethink diagnosis, review family psychiatric history
- ▶ Re-assess your end points Evaluate medical problems
- ▶ Review all medications
- ▶ Address life stressors & psychosocial factors
- ▶ Check blood levels
- ▶ Generic vs. brand name formulation ("bioavailability")
- ▶ Assess dosage of current medication
- ▶ Discuss medication compliance
- ▶ Consider GI issues (malabsorption after gastric bypass, gut biome)
- ▶ Mediterraneanize your patient's diet ("anti-inflammatory" diet)

Examples:

Rethink diagnosis: evidence seems to show that bipolar depression responds to different meds vs. unipolar depression; also, 'are there psychotic features present'

Re-assess your end points: What level of remission can you realistically expect?

"Remission" for you or me might be different from your chronic, persistently seriously ill patient; does every child have to get into Harvard, or will you be happy if they get into Vanderbilt? But, lowering expectations shouldn't really be your first strategy with TRD, even though it's listed up here near the top.

Evaluate medical problems: common examples include: anemia, avitaminosis D, thyroid problems, pancreatic cancer, pituitary adenoma,

Review all medications: eg, "beta blocker blues" and other depressogenic or anxiogenic meds; chronic benzodiazepine usage

Life stressors: divorce, marriage, etc.

Blood levels: lithium, VPA, "window" for nortryptiline

Generic vs. brand name: rarely, these days, but still worth thinking about. Used to be a notable difference between Depakote and generic valproic acid; still see that occasionally. Another one you might see is generic Bupropion vs. brand-name Wellbutrin

Current dosage: E.G., MOST AD's are Rx'ed by non-psychiatrists, yet non-psychiatrists are still often reluctant to increase dose to a therapeutic level

Medication compliance: non-compliance or partial compliance is the rule rather than the exception

Substance abuse: appallingly common in US society

GI issues: microbial dysbiosis associated with anxiety, depression, OCD symptoms; “gut brain axis”: gut microbiome influences absorption of nutrients, vagus nerve signals, overall serotonin regulation

.

Partial responders things to think about (slide 2)

- ▶ Identify drug & alcohol use
- ▶ Add exercise
- ▶ Address "sleep hygiene"
- ▶ Keep a "one positive thing" journal or a "SAGE" journal
- ▶ Increase "dose" of psychotherapy
- ▶ Pastor's Potent Micronutrient Potion: Supplement with Vit D, folate, Magnesium, B12, Zinc, PUFA's, Co-Q-10
- ▶ Bright light/dark night therapy
- ▶ Negative ions
- ▶ Music & art, aromatherapy
- ▶ Logotherapy (re-connecting with purpose in life)

Partial responders things to think about (slide 3)

- ▶ Decrease dose (e.g., insomnia, HA, agitation associated with excess 5HT)
- ▶ Change to a different antidepressant
- ▶ Use the "rocket fuel" option (combine antidepressants to hit all NT's at once)
- ▶ Carefully review past Hx of medication response (adequate trials, confounders)
- ▶ Address target symptoms or side effects directly (e.g., sleep)
- ▶ Vit D, L-methylfolate, B-12, cholesterol, potassium, OFA's (Omega Fatty Acids)
- ▶ Add Lithium
- ▶ Add Thyroid hormone, Testosterone (for men)
- ▶ Antipsychotics (SGA's) – Abilify, Seroquel, Latuda
- ▶ Intranasal Esketamine
- ▶ Stimulants
- ▶ ECT, TMS, bright light therapy ("10,000 LUX")
- ▶ Check for inflammatory markers (C-reactive protein), add Celecoxib or switch to a TCA

What is an "augmentation strategy": use of a drug or modality that is not generally considered an efficacious treatment for depression in and of itself, but acts synergistically for additive effect when added to an existing depression treatment.

All these maneuvers fall into the hand acronym of: "S.C.A.R.I.E.R." –

- Switching
- Combining
- Augmenting
- Referring (to a specialist)
- Inquiring (as to compliance, substance use)
- Empathizing (counseling, therapy, dealing with ongoing crises or trauma)
- Rediagnosing (consider both medical & psychiatric diagnoses)


Suggested augmentation sequence from Harvard review 2017

- ▶ Lithium
- ▶ Wellbutrin
- ▶ Ritalin
- ▶ SGA (Abilify, Seroquel, Latuda, Geodon)
- ▶ Lamictal
- ▶ B (methcobalamin, methyfolate) & D vitamins, Magnesium, Zinc
- ▶ Thyroid hormone (Triiodothyroxine)
- ▶ Estrogen/testosterone
- ▶ Pindolol

Pindolol (Visken) = non-selective beta-blocker with “ISA” (Intrinsic Sympathomimetic Activity), therefore has “partial agonist” activity


Pindolol

- ▶ Beta-blocker drug
- ▶ Anti-adrenergic
- ▶ Non-selective
- ▶ More Lipophilic than not
- ▶ Anti-hypertensive
- ▶ Has "ISA"
- ▶ **Intrinsic Sympathomimetic Activity**
- ▶ Potentiates the SSRI response for some patients
- ▶ Helps SSRI's work faster?



Pindolol & Beta-Adrenergic Blockade

- ▶ **Non-selective** includes Beta-1 and Beta-2 activity
 - ▶ Negative inotrope
 - ▶ Negative chronotrope
 - ▶ Bronchiolar broncho-constriction
- ▶ **Selective** includes Beta-1 only (cardiac)
 - ▶ **Propranolol** is contra-indicated with patients with bronchial asthma
- ▶ Beta-blockers further classified by hydrophilic vs. lipophilic
 - ▶ **Atenolol** is most hydrophilic
 - ▶ **Propranolol** is most lipophilic



Three features of every Beta-blocker:


- (1) Selective vs. non-selective
- (2) With ISA or without ISA
- (3) Hydrophilic (won't cross BBB) or hydrophobic (will cross BBB)

Atenolol: an outstanding example of pharmacokinetics at work: Atenolol, being most hydrophilic, is least likely to cross the blood brain barrier, and studies find it has the lowest incidence of CNS side effects (lethargy, low-level depression euphioniously known as the "beta blocker blues").


So if you want to treat blood pressure alone and avoid potential CNS complications, your best bet is Atenolol.

Pindolol

Serotonin:



Pindolol:



It defies logic at first: why should a drug (Pindolol) that in essence antagonizes sympathetic-adrenergic activity **also** have effects that increase catecholaminergic activity?

The answer, like that annoying-ly ubiquitous Ed Sheeran song, lies in “the shape of you” – well, the shape of the molecule, actually.


The shape of the molecule determines whether it fits into a particular neuro-receptor protein or not – in a lock and key fashion; we can all see this with our own eyes, even if we never took a chemistry class.

[observe the two rings in comparing Pindolol and Serotonin – ignore the “moieties” that are attached]


[Go to next slide]

Pindolol & Propranolol: A tale of two Beta-blockers

Propranolol:




Pindolol:



I think the study in your bibliography finds that only “high dose” Pindolol is effective, i.e., 7.5 mg/day vs. 5 mg.

Inflammatory markers in TRD

- ▶ A majority of patients with depression who are treatment-resistant have positive markers for systemic inflammation
 - ▶ C-reactive protein
 - ▶ Interleukin-6
 - ▶ Tumor Necrosis Factor-alpha
- ▶ Non-depressed people, given Interferon (IF), experience depression
- ▶ For depressed patients with CRP > 2 mg/L, Nortriptyline (a TCA) works and SSRI's don't
- ▶ When CRP is < 2, SSRI's are superior to TCA's
- ▶ TNF-alpha blocker is superior to placebo
- ▶ Check inflammatory markers and Rx adjunctive Celecoxib (Celebrex) if elevated



TRD = Treatment Resistant Depression

We are referring to “chronic and systemic” inflammatory states, as opposed to temporary and localized inflammatory states (like a paper cut or a toe stub). An endocrine, immune system, and CNS response to some sort of stress or irritation. The body mobilizes its resources to fight off the potential threat but doesn't shut down the inflammatory response over time – kind of like what we're more familiar with, when the stress response persists over time (reference Sapolsky's book “Why don't Zebras get ulcers”).

Chronic systemic inflammatory disease may affect the GI, cardiovascular, or CNS systems. Turns out more than half of TRD patients have positive markers – called cytokines - for systemic inflammation: CRP, IL-6, TNF-alpha.

Slide shows just one small part of a very complex cascade or chain reaction in the body; inflammation can lead to blood clotting, vasoconstriction, decomposition of the mucosal lining of the GI tract, arthralgia, fatigue, and – we put a little “question mark” here – depression.

TNF-alpha blocker is: Infliximab. “Interferons” are proteins produced by the body in response to viral infections and function to “interfere” with the replication viral pathogens, ergo the name “Interferon”. IF’s are members of the cytokine family and generally pro-inflammatory.

Reference: Trends in Immunology, [Volume 33, Issue 11](#), p571–577, November 2012

Review: **Interleukin-6: from an inflammatory marker to a target for inflammatory diseases**

Mercedes Rincon

Department of Medicine/Immunobiology, University of Vermont, Burlington, VT
05405, USA

DOI: <http://dx.doi.org/10.1016/j.it.2012.07.003>

MDD with mixed features

"Mixed features" include:

- ▶ Racing thoughts/flight of ideas
- ▶ Increase in energy
- ▶ Periods of elevated or expansive mood
- ▶ Distractibility
- ▶ Decreased need for sleep

Risk factors for progression to bipolar disorder:

- ▶ Mixed features
- ▶ Earlier onset of depression (before age 19)
- ▶ Family history of Bipolar disorder
- ▶ Psychosis or Suicidality
- ▶ Delayed sleep phase
- ▶ Anxiety or substance use disorder
- ▶ History of child abuse
- ▶ Loss, injury, stressors, divorce
- ▶ Poor response to antidepressant
- ▶ AD-induced mania
- ▶ Autumnal (vs. vernal) onset


Up to one-third of patients diagnosed with MDD are found to eventually merit a diagnosis of Bipolar Disorder (J Clin Psychiatry 78.8 Sept.Oct 2017). For one thing, patients tend to under-report hypomanic symptoms such as hypomanic symptoms such as elevated mood, reckless behavior, or increased activity. We can think of a continuum from unipolar depression ("MDD"), to MDD with mixed features, to Bipolar type II, to classic Bipolar disorder with manic as well as depressive episodes. Understanding this continuum is extremely important when treating depression because it now appears that patients with bipolar or mixed features respond to different medications than patient with unipolar depression.

These findings are entirely counter-intuitive to me, for two reasons. One, SSRI's are so widely effective that it seems that everyone with depression deserves a trial of SSRI therapy before moving on to more complex or uncommon treatments. Two, I feel why treat symptoms or diagnoses that haven't yet – and may never – reveal themselves? If a patient is depressed, we'll treat the depression, and THEN if other symptoms appear, we'll address those if and when they arise. However, evidence is accumulating that antidepressants including TCA's and SSRI's are less effective than the SGA's for treating depression with mixed features. The SGA often needs augmentation and the algorithm-recommended augmenting medicine is not an SSRI but rather a mood-

stabilizer such as Lamictal, Depakote, or Tegretol. Lithium, too. Overall best evidenced-based response rates for depression in BPD = OFC, Lithium, Seroquel, Lamictal, followed by VPA and then Abilify.

So we've got to know what mixed features are, how to look for them, and keep our noses to the ground and our index of suspicion for mixed features and bipolarity high.


It is wise to remember that the spectrum of mood disorders is dynamic and evolving and a single office-visit, cross-sectional evaluation can be misleading. Obtain a detailed personal history, including family psychiatric history, and longitudinal follow-up.



From: Hu, et al, Mixed specifier for bipolar mania and depression: highlights of DSM-5 changes and implications for diagnosis and treatment in primary care, Primary Care Companion CNS Disorders 2014; 16(2): doi: 10.4088/PCC.12r01599.

You've correctly diagnosed your patient as MDD with "mixed features". According to expert guidelines, the best choice of medication is:

- ▶ (A) an Antidepressant with mixed Serotonin and Norepinephrine activity
- ▶ (B) a Psychostimulant with mixed amphetamine salts
- ▶ (C) a Benzodiazepine initially, followed after 1 to 2 weeks by mixing in an antidepressant
- ▶ (D) a second generation antipsychotic such as Latuda, Seroquel, or Abilify



Answer: D

“Joel, an outwardly successful professional, has had recurrent depression since the autumn that he began high school. He’s now 28 years old and has failed three courses of antidepressants. Current symptoms include intense anxiety and sleep disturbance. There’s a history of frequent suicidal thoughts, and recently he’s begun to wonder if the government is spying on him.” His father was diagnosed with bipolar disorder last year.

To me, it still seems like “everyone” – or every depressed patient – deserves a trial of an SSRI before we get into more complicated or risky medication strategies. But again, RCT’s and algorithms find better evidence for initial treatment with an SGA with proven efficacy for MDD with mixed features and/or depression in the context of bipolar disorder.

Mood stabilizers & SGA's for bipolar depression

Teaching Points

Mood stabilizers are foundational agents and should be considered first line treatments, with the strongest evidence supporting the use of lithium and lamotrigine.

Emerging data suggest atypical antipsychotics provide benefit in acute bipolar depression, with the strongest evidence supporting the use of quetiapine monotherapy and the olanzapine plus fluoxetine combination.

The utility of adjunctive antidepressants in bipolar depression is controversial, as these agents can yield switching into mania or hypomania in some patients.

Lamotrigine Maintenance Therapy Well-Tolerated in Bipolar II Disorder

Adverse event	Patients (%)
Dizziness	3 (13.6)
Ataxia	2 (9.1)
Somnolence	1 (4.5)
Headache	1 (4.5)
Insomnia	1 (4.5)

Herman E, Hovorka J, Sirovacka J, et al. Poster presented at 12th World Congress of Psychiatry, held in Yokohama, Japan, on August 24-29, 2002.

Indeed, the use of antidepressants may not only induce switching, but evidence suggests they are also linked to an increased likelihood of rapid cycling.

Acronyms vs. Algorithms: “SCARIER R WE” approach

▶ **Switching**

▶ Options include: 2nd SSRI, SNRI, TCA, Atypical AD, SGA, mood stabilizer

A clash of paradigms: Acronyms or Algorithms for Tx of antidepressant non-responders?

SCARIER R WE =

Switching = options include: (1) second SSRI, (2) SNRI, (3) TCA, (4) atypical AD, (5) SGA, (6) mood stabilizer

Combining = options include: pretty much all of the above, generally an AD from a different class and MOA

Augmenting = generally with agents that are not AD's in themselves, e.g. (1) T3, (2) Pindolol, (3) lithium, (4) OFA's, (5) stimulants (methylphenidate, modafinil)

Referring = call your friendly neighborhood psychiatrist

Investigating = i.e., asking about compliance (lower when PCP is the prescriber vs. psychiatric prescriber), asking about drug and alcohol use

Empathizing = a tortured way of mentioning that psychotherapy should be a part of nearly every treatment plan for depression

Re-diagnosing = consider both medical diagnoses, deficiency syndromes, and differential psychiatric diagnoses

Receptor supersensitivity = consider effects of both antidepressant withdrawal and re-starting; serotonin supersensitivity can look like anxiety, dysphoria, insomnia – i.e., depression

Waiting = not evaluated in STAR-D, after 10 weeks of non-response, waiting another 6 weeks was as effective as any switching tactic attempted

Escalating the dose = related to “waiting”, increase dose if tolerated by side effect and safety considerations

Acronyms vs. Algorithms: “SCARIER R WE” approach

- ▶ **Switching**
 - ▶ Options include: 2nd SSRI, SNRI, TCA, Atypical AD, SGA, mood stabilizer
- ▶ **Combining**
 - ▶ Options include: all of the above but generally an AD from a different class and MOA

A clash of paradigms: Acronyms or Algorithms for Tx of antidepressant non-responders?

SCARIER R WE =

Switching = options include: (1) second SSRI, (2) SNRI, (3) TCA, (4) atypical AD, (5) SGA, (6) mood stabilizer

Combining = options include: pretty much all of the above, generally an AD from a different class and MOA

Augmenting = generally with agents that are not AD's in themselves, e.g. (1) T3, (2) Pindolol, (3) lithium, (4) OFA's, (5) stimulants (methylphenidate, modafinil)

Referring = call your friendly neighborhood psychiatrist

Investigating = i.e., asking about compliance (lower when PCP is the prescriber vs. psychiatric prescriber), asking about drug and alcohol use

Empathizing = a tortured way of mentioning that psychotherapy should be a part of nearly every treatment plan for depression

Re-diagnosing = consider both medical diagnoses, deficiency syndromes, and differential psychiatric diagnoses

Receptor supersensitivity = consider effects of both antidepressant withdrawal and re-starting; serotonin supersensitivity can look like anxiety, dysphoria, insomnia – i.e., depression

Waiting = not evaluated in STAR-D, after 10 weeks of non-response, waiting another 6 weeks was as effective as any switching tactic attempted

Escalating the dose = related to “waiting”, increase dose if tolerated by side effect and safety considerations

Acronyms vs. Algorithms: “SCARIER R WE” approach

- ▶ **Switching**
 - ▶ Options include: 2nd SSRI, SNRI, TCA, Atypical AD, SGA, mood stabilizer
- ▶ **Combining**
 - ▶ Options include: all of the above but generally an AD from a different class and MOA
- ▶ **Augmenting**
 - ▶ Augmenting involves agents that are not truly antidepressants in themselves: T3, Pindolol, Lithium, OFA's, stimulants (methylphenidate, modafinil)

A clash of paradigms: Acronyms or Algorithms for Tx of antidepressant non-responders?

SCARIER R WE =

Switching = options include: (1) second SSRI, (2) SNRI, (3) TCA, (4) atypical AD, (5) SGA, (6) mood stabilizer

Combining = options include: pretty much all of the above, generally an AD from a different class and MOA

Augmenting = generally with agents that are not AD's in themselves, e.g. (1) T3, (2) Pindolol, (3) lithium, (4) OFA's, (5) stimulants (methylphenidate, modafinil)

Referring = call your friendly neighborhood psychiatrist

Investigating = i.e., asking about compliance (lower when PCP is the prescriber vs. psychiatric prescriber), asking about drug and alcohol use

Empathizing = a tortured way of mentioning that psychotherapy should be a part of nearly every treatment plan for depression

Re-diagnosing = consider both medical diagnoses, deficiency syndromes, and differential psychiatric diagnoses

Receptor supersensitivity = consider effects of both antidepressant withdrawal and re-starting; serotonin supersensitivity can look like anxiety, dysphoria, insomnia – i.e., depression

Waiting = not evaluated in STAR-D, after 10 weeks of non-response, waiting another 6 weeks was as effective as any switching tactic attempted

Escalating the dose = related to “waiting”, increase dose if tolerated by side effect and safety considerations

Acronyms vs. Algorithms: “SCARIER R WE” approach

- ▶ **Switching**
 - ▶ Options include: 2nd SSRI, SNRI, TCA, Atypical AD, SGA, mood stabilizer
- ▶ **Combining**
 - ▶ Options include: all of the above but generally an AD from a different class and MOA
- ▶ **Augmenting**
 - ▶ Augmenting involves agents that are not truly antidepressants in themselves: T3, Pindolol, Lithium, OFA's, stimulants (methylphenidate, modafinil)
- ▶ **Referring**
 - ▶ Call your friendly neighborhood psychiatrist

A clash of paradigms: Acronyms or Algorithms for Tx of antidepressant non-responders?

SCARIER R WE =

Switching = options include: (1) second SSRI, (2) SNRI, (3) TCA, (4) atypical AD, (5) SGA, (6) mood stabilizer

Combining = options include: pretty much all of the above, generally an AD from a different class and MOA

Augmenting = generally with agents that are not AD's in themselves, e.g. (1) T3, (2) Pindolol, (3) lithium, (4) OFA's, (5) stimulants (methylphenidate, modafinil)

Referring = call your friendly neighborhood psychiatrist

Investigating = i.e., asking about compliance (lower when PCP is the prescriber vs. psychiatric prescriber), asking about drug and alcohol use

Empathizing = a tortured way of mentioning that psychotherapy should be a part of nearly every treatment plan for depression

Re-diagnosing = consider both medical diagnoses, deficiency syndromes, and differential psychiatric diagnoses

Receptor supersensitivity = consider effects of both antidepressant withdrawal and re-starting; serotonin supersensitivity can look like anxiety, dysphoria, insomnia – i.e., depression

Waiting = not evaluated in STAR-D, after 10 weeks of non-response, waiting another 6 weeks was as effective as any switching tactic attempted

Escalating the dose = related to “waiting”, increase dose if tolerated by side effect and safety considerations

Acronyms vs. Algorithms: “SCARIER R WE” approach

- ▶ **Switching**
 - ▶ Options include: 2nd SSRI, SNRI, TCA, Atypical AD, SGA, mood stabilizer
- ▶ **Combining**
 - ▶ Options include: all of the above but generally an AD from a different class and MOA
- ▶ **Augmenting**
 - ▶ Augmenting involves agents that are not truly antidepressants in themselves: T3, Pindolol, Lithium, OFA's, stimulants (methylphenidate, modafinil)
- ▶ **Referring**
 - ▶ Call your friendly neighborhood psychiatrist
- ▶ **Investigating**
 - ▶ i.e., ask about compliance, drug & alcohol use

A clash of paradigms: Acronyms or Algorithms for Tx of antidepressant non-responders?

SCARIER R WE =

Switching = options include: (1) second SSRI, (2) SNRI, (3) TCA, (4) atypical AD, (5) SGA, (6) mood stabilizer

Combining = options include: pretty much all of the above, generally an AD from a different class and MOA

Augmenting = generally with agents that are not AD's in themselves, e.g. (1) T3, (2) Pindolol, (3) lithium, (4) OFA's, (5) stimulants (methylphenidate, modafinil)

Referring = call your friendly neighborhood psychiatrist

Investigating = i.e., asking about compliance (lower when PCP is the prescriber vs. psychiatric prescriber), asking about drug and alcohol use

Empathizing = a tortured way of mentioning that psychotherapy should be a part of nearly every treatment plan for depression

Re-diagnosing = consider both medical diagnoses, deficiency syndromes, and differential psychiatric diagnoses

Receptor supersensitivity = consider effects of both antidepressant withdrawal and re-starting; serotonin supersensitivity can look like anxiety, dysphoria, insomnia – i.e., depression

Waiting = not evaluated in STAR-D, after 10 weeks of non-response, waiting another 6 weeks was as effective as any switching tactic attempted

Escalating the dose = related to “waiting”, increase dose if tolerated by side effect and safety considerations

Acronyms vs. Algorithms: “SCARIER R WE” approach

- ▶ **Switching**
 - ▶ Options include: 2nd SSRI, SNRI, TCA, Atypical AD, SGA, mood stabilizer
- ▶ **Combining**
 - ▶ Options include: all of the above but generally an AD from a different class and MOA
- ▶ **Augmenting**
 - ▶ Augmenting involves agents that are not truly antidepressants in themselves: T3, Pindolol, Lithium, OFA's, stimulants (methylphenidate, modafinil)
- ▶ **Referring**
 - ▶ Call your friendly neighborhood psychiatrist
- ▶ **Investigating**
 - ▶ i.e., ask about compliance, drug & alcohol use
- ▶ **Empathizing**
 - ▶ A tortured way of noting that psychotherapy should be part of nearly every depression Tx plan

A clash of paradigms: Acronyms or Algorithms for Tx of antidepressant non-responders?

SCARIER R WE =

Switching = options include: (1) second SSRI, (2) SNRI, (3) TCA, (4) atypical AD, (5) SGA, (6) mood stabilizer

Combining = options include: pretty much all of the above, generally an AD from a different class and MOA

Augmenting = generally with agents that are not AD's in themselves, e.g. (1) T3, (2) Pindolol, (3) lithium, (4) OFA's, (5) stimulants (methylphenidate, modafinil)

Referring = call your friendly neighborhood psychiatrist

Investigating = i.e., asking about compliance (lower when PCP is the prescriber vs. psychiatric prescriber), asking about drug and alcohol use

Empathizing = a tortured way of mentioning that psychotherapy should be a part of nearly every treatment plan for depression

Re-diagnosing = consider both medical diagnoses, deficiency syndromes, and differential psychiatric diagnoses

Receptor supersensitivity = consider effects of both antidepressant withdrawal and re-starting; serotonin supersensitivity can look like anxiety, dysphoria, insomnia – i.e., depression

Waiting = not evaluated in STAR-D, after 10 weeks of non-response, waiting another 6 weeks was as effective as any switching tactic attempted

Escalating the dose = related to “waiting”, increase dose if tolerated by side effect and safety considerations

Acronyms vs. Algorithms: “SCARIER R WE” approach

- ▶ **Switching**
 - ▶ Options include: 2nd SSRI, SNRI, TCA, Atypical AD, SGA, mood stabilizer
- ▶ **Combining**
 - ▶ Options include: all of the above but generally an AD from a different class and MOA
- ▶ **Augmenting**
 - ▶ Augmenting involves agents that are not truly antidepressants in themselves: T3, Pindolol, Lithium, OFA's, stimulants (methylphenidate, modafinil)
- ▶ **Referring**
 - ▶ Call your friendly neighborhood psychiatrist
- ▶ **Investigating**
 - ▶ i.e., ask about compliance, drug & alcohol use
- ▶ **Empathizing**
 - ▶ A tortured way of noting that psychotherapy should be part of nearly every depression Tx plan
- ▶ **Re-diagnosing**
 - ▶ Consider: medical diagnoses, deficiency syndromes, & differential psychiatric diagnoses

A clash of paradigms: Acronyms or Algorithms for Tx of antidepressant non-responders?

SCARIER R WE =

Switching = options include: (1) second SSRI, (2) SNRI, (3) TCA, (4) atypical AD, (5) SGA, (6) mood stabilizer

Combining = options include: pretty much all of the above, generally an AD from a different class and MOA

Augmenting = generally with agents that are not AD's in themselves, e.g. (1) T3, (2) Pindolol, (3) lithium, (4) OFA's, (5) stimulants (methylphenidate, modafinil)

Referring = call your friendly neighborhood psychiatrist

Investigating = i.e., asking about compliance (lower when PCP is the prescriber vs. psychiatric prescriber), asking about drug and alcohol use

Empathizing = a tortured way of mentioning that psychotherapy should be a part of nearly every treatment plan for depression

Re-diagnosing = consider both medical diagnoses, deficiency syndromes, and differential psychiatric diagnoses

Receptor supersensitivity = consider effects of both antidepressant withdrawal and re-starting; serotonin supersensitivity can look like anxiety, dysphoria, insomnia – i.e., depression

Waiting = not evaluated in STAR-D, after 10 weeks of non-response, waiting another 6 weeks was as effective as any switching tactic attempted

Escalating the dose = related to “waiting”, increase dose if tolerated by side effect and safety considerations

“SCARIER R WE” (continued)

- ▶ **Receptor supersensitivity**
- ▶ After stopping or re-starting, consider both AD withdrawal and 5-HT receptor supersensitivity (anxiety, insomnia, dysphoria)

Receptor supersensitivity = consider effects of both antidepressant withdrawal and re-starting; serotonin supersensitivity can look like anxiety, dysphoria, insomnia – i.e., depression

Waiting = not evaluated in STAR-D, after 10 weeks of non-response, waiting another 6 weeks was as effective as any switching tactic attempted

Escalating the dose = related to “waiting”, increase dose if tolerated by side effect and safety considerations

Antidepressant discontinuation Syndrome

- ▶ “Discontinuation” vs. “withdrawal”
- ▶ Usually mild
- ▶ Lasts from 1 day to 3 weeks (average of a week to 10 days)
- ▶ Risk factors:
 - ▶ Feeling better – go off meds
 - ▶ Become pregnant – go off meds suddenly
- ▶ Symptom cluster: next slide



“Discontinuation” vs. “Withdrawal”: separates AD’s from drugs of abuse (no “cravings”, no search for highs, no addictive properties). S. you “withdraw” from heroin, you “discontinue” Paxil.

Antidepressant discontinuation Syndrome

- ▶ **Sensory Symptoms**
 - ▶ Paresthesias
 - ▶ Numbness
 - ▶ Shock-like sensations ("brain zaps")
 - ▶ Visual trails (Palinopsia)
 - ▶ Rushing noise in head
- ▶ **Disequilibrium**
 - ▶ Light-headedness
 - ▶ Dizziness
 - ▶ Vertigo
- ▶ **Affective symptoms**
 - ▶ Irritability, anxiety
 - ▶ tearfulness
- ▶ **General somatic symptoms**
 - ▶ Lethargy
 - ▶ Headache
 - ▶ Tremor
 - ▶ Sweating
 - ▶ Anorexia
 - ▶ "Flu-like" symptoms
- ▶ **GI symptoms**
 - ▶ Nausea, vomiting
 - ▶ Diarrhea
- ▶ **Sleep disturbance**
 - ▶ Insomnia
 - ▶ Nightmares, increased dreaming

Six groups of symptoms

Some Sx look like depression itself, others are somewhat unique ("shock-like sensations", "brain zaps"); suspect AD Discontinuation Syndrome by history and timing

Antidepressant discontinuation Syndrome

- ▶ **DDX:**
 - ▶ depressive relapse,
 - ▶ Serotonin syndrome
- ▶ **Tx considerations:**
 - ▶ Patient education
 - ▶ Fluoxetine: requires no taper
 - ▶ Reassurance
 - ▶ Restart & change to a slow taper

Antidepressant discontinuation symptoms

- F = flu like symptoms
- I = insomnia
- N = nausea
- I = imbalance
- S = sensory disturbances
- H = hyperarousal (anxiety) (Gelenberg, 1998 cited in Carson, 2008, p. 432)

“SCARIER R WE” (continued)

- ▶ **Receptor supersensitivity**
 - ▶ After stopping or re-starting, consider both AD withdrawal and 5-HT receptor supersensitivity (anxiety, insomnia, dysphoria)
- ▶ **Waiting**
 - ▶ Not a part of STAR-D, after 10 weeks of non-response, waiting another 6 weeks as effective as any switching tactic attempted

Receptor supersensitivity = consider effects of both antidepressant withdrawal and re-starting; serotonin supersensitivity can look like anxiety, dysphoria, insomnia – i.e., depression

Waiting = not evaluated in STAR-D, after 10 weeks of non-response, waiting another 6 weeks was as effective as any switching tactic attempted; “Waiting” is derived from the axiom in medicine, “Don’t just do something, stand there.”

Escalating the dose = related to “waiting”, increase dose if tolerated by side effect and safety considerations

“SCARIER R WE” (continued)

- ▶ **Receptor supersensitivity** ▶ After stopping or re-starting, consider both AD withdrawal and 5-HT receptor supersensitivity (anxiety, insomnia, dysphoria)
- ▶ **Waiting** ▶ Not a part of STAR-D, after 10 weeks of non-response, waiting another 6 weeks as effective as any switching tactic attempted
- ▶ **Escalating dose** ▶ Related to “waiting”, increase dose if tolerated by side effect and safety considerations

Receptor supersensitivity = consider effects of both antidepressant withdrawal and re-starting; serotonin supersensitivity can look like anxiety, dysphoria, insomnia – i.e., depression

Waiting = not evaluated in STAR-D, after 10 weeks of non-response, waiting another 6 weeks was as effective as any switching tactic attempted

Escalating the dose = related to “waiting”, increase dose if tolerated by side effect and safety considerations

Antipsychotics

The 1st Antipsychotic: Thorazine

- ▶ First-generation antipsychotics (FGA)
- ▶ Side effects include:
 - ▶ Movement disorders
 - ▶ Endocrine
 - ▶ Sedation
 - ▶ Anticholinergic




Dopamine blockade provides treatment for hallucinations, delusions, agitation, cognitive disorganization associated with psychosis.

FGA's and SGA's equally efficacious for positive symptoms, SGA's may be somewhat more efficacious for negative symptoms. Otherwise, equally efficacious.

SGA's have 5-HT activity as well as DA activity; some have indications for Tx of depression.

EPSE (extrapyramidal side effects)



Pyramidal and Extrapyramidal

Upper Motor Neurons

Pyramidal


direct corticospinal tract

- Fine coordination motion

Extrapyramidal

indirect cortico-bulbo-spinal tracts (vestibular/ reticular tracts)

- Balance, posture, coordination



Describe the four types of EPSE.

Acute dystonia: eye rolling back in head, tongue protrusion, paraspinal or neck muscle contractions

Akathisia: restlessness, foot-tapping, can't sit still, "inner" restlessness

Parkinsonism: shuffling gait, loss of postural adjustment, stiffness, mask-like faces, slowness, resting tremor

Tardive Dyskinesia: puckering, chewing, grimmacing; abnormal limb or truncal movements

Mention where the term "extrapyramidal" comes from.

Match the abnormal finding to its underlying EPSE:



- | | | |
|--|--|--------------------|
| A. Oculogyric crisis, tongue protrusion, opisthotonus | | Tardive Dyskinesia |
| B. Shuffling gait, bradykinesia, festinating gait, dysdiadochokinesia | | Parkinsonism |
| C. "sewing needle leg", inability to sit still, restlessness | | Akathisia |
| D. Orofacial dyskinesias (puckering, masticating, grimacing), choreoathetoid limb or truncal movements | | Acute Dystonia |


Festinating gait: a stiff, forward-leaning gait, often on tiptoes, with short, accelerating steps, and difficulty stopping; due to the loss of postural reflexes in Parkinson's disease or drug-induced Parkinsonism.

Dysdiadochokinesia = impaired rapid alternating movements

Overall incidence of TD is up to 25% of schizophrenics Tx'ed with long-term neuroleptics; however, incidence is approximately 15% in treatment-naïve schizophrenics. Elderly and edentulous are more at risk.

TD can be induced by chronic phenothiazine Rx for nausea.

Time line for appearance of EPSE:





A Take-away: not all neuroleptic-induced movement disorder is T.D.

Another take-away: avoid saying “this could be tardive dyskinesia” if the patient’s only been on a neuroleptic for a few days or weeks.

Another take-away: EPSE and fear of T.D. is a major reason why the SGA’s are Rx’ed today more commonly than the FGA’s – it’s an extremely bad advertisement for you as a physician to have a patient walking (or shuffling) around with severe T.D. and everyone is point at the patient saying, “Oh, that fellow, that’s one of Dr. Pastor’s patients”

1st & 2nd generation antipsychotics



The key difference between 1GA and 2GA antipsychotics:

DA blockage only vs. DA + 5HT activity

This difference is reflected in the key S/E profile

2GA purportedly improves negative symptoms and cognitive dysfunction of psychosis.

Second-generation antipsychotics ("atypicals")

Table 2. Select Antipsychotic Agents

Traditional (First Generation) Antipsychotics
Chlorpromazine (Thorazine)
Fluphenazine (Prolixin, Permittil), fluphenazine decanoate
Haloperidol (Haldol), haloperidol decanoate
Loxapine (Loxitane)
Mesoridazine besylate (Serentil)
Molindone (Molan)
Perphenazine (Trilafon)
Thioridazine (Mellaril)
Thiothixene (Navane)
Trifluoperazine (Stelazine)
Atypical (Second Generation) Antipsychotics
Aripiprazole (Abilify, Abilify Discmelt)
Clozapine (Clozaril, FazaClo)
Iliperidone (Fanapt, Fanapt Titration Pack)
Olanzapine (Zyprexa)
Paliperidone (Invega), paliperidone palmitate (Invega Sustenna)
Quetiapine (Seroquel, Seroquel XR)
Risperidone (Risperdal, Risperdal Consta, Risperdal M-TAB)
Ziprasidone (Geodon)


Source: References 2,15.

	 SEDATION	 WEIGHT GAIN	 EPS
Best choice  Worst choice	Aripiprazole	Aripiprazole	Clozapine
	Iliperidone	Lurasidone	Iliperidone
	Lurasidone	Ziprasidone	Quetiapine
	Paliperidone	Asenapine	Aripiprazole
	Risperidone	Iliperidone	Asenapine
	Ziprasidone	Paliperidone	Lurasidone
	Asenapine	Risperidone	Olanzapine
	Olanzapine	Quetiapine	Ziprasidone
	Clozapine	Clozapine	Paliperidone
	Quetiapine	Olanzapine	Risperidone

SGA's

- ▶ **Zyprexa (Olanzapine)**
 - ▶ Very sedating
 - ▶ Instantly dissolving preparation called "Zydis"
 - ▶ Weight gain & sedation
 - ▶ Good for highly agitated patients
- ▶ **Seroquel (Quetiapine)**
 - ▶ Very wide dose range provides flexibility (25 to 800 mg daily)
 - ▶ Will put anyone to sleep
 - ▶ Proven efficacy for depression
- ▶ **Risperdal (Risperidone)**
 - ▶ Low risk of metabolic syndrome but
 - ▶ Higher risk of EPSE & hyperprolactinemia-induced gynecomastia
- ▶ **Abilify (Aripiprazole)**
 - ▶ Not very sedating
 - ▶ Not associated with weight gain
 - ▶ Proven efficacy for depression
- ▶ **Lurasidone (Latuda)**
 - ▶ No weight gain
 - ▶ Proven efficacy for depression
 - ▶ 1st line for BPD (with Lamictal)
- ▶ **Clozaril (Clozapine)**
 - ▶ Treatment-resistant Schizophrenia
 - ▶ Needs blood monitoring for agranulocytosis
 - ▶ Weight gain, S-T prolongation

Pop Quiz: match the medicine with its relevant lab test



Multiple indications for SGA's




- ▶ Psychosis (schizophrenia, schizoaffective disorder, drug-induced psychosis)
- ▶ Bipolar mania
- ▶ Bipolar depression
- ▶ Borderline personality disorder
 - ▶ Targeting: suspiciousness, paranoia, primitive thinking, dissociative states
- ▶ Agitation & insomnia

Lurasidone (Latuda) should be added to “Table 1”

Additional uses of SGA's:

- Psychosis (schizophrenia, schizoaffective disorder, drug-induced psychosis)
- Bipolar mania
- Bipolar depression
- Borderline personality disorder (target Sx = suspiciousness, paranoia, all-or-none primitive thinking, dissociative states)
- Agitation & insomnia

Pop quiz



▶ Which medication is **incorrectly** paired with its notable side effect?

- A. **Zyprexa** – weight gain
- B. **Haldol** – acute dystonia
- C. **Seroquel** – sedation
- D. **Clozaril** – agranulocytosis
- E. **Lithium** – tardive dyskinesia

▶ **Correct answer: E**

Bipolar disorder: Lithium

Lithium

- ▶ Naturally occurring mineral
- ▶ Formerly in 7-Up
- ▶ The first mood stabilizer
- ▶ Neuroprotective
- ▶ Independent anti-suicidal effects
- ▶ Rapid withdrawal may precipitate suicidality
- ▶ Lowers dementia risk
- ▶ Lowers rehospitalization risk
- ▶ Renally excreted, H₂O soluble
- ▶ **Lowest therapeutic index**

The "gold standard" in bipolar disorder treatment:



2017 Review of 4 major treatment algorithms:

- Lithium is the "gold standard" in BPD Tx
- Need justification NOT to use lithium
- Decreased suicide risk independent of Dx
- Increased neuroprotective effects
- May be combined with other mood stabilizers
- Discontinue SLOWLY to avert suicidality
- HS dosing to minimize renal effects
- LABS: TFT, creatinine, Li levels, HCG, EKG, CBC

Many Lithium enthusiasts would like to see Lithium classified by the USDA as an "essential trace element" like other metals such as Zinc, copper, selenium, and Magnesium.

Zurich cohort: lowers dementia risk.

Clin Psy News: 50% reduction in hospitalization of depressed patients

Lithium has a potential side effect of elevating white blood cell count (has been used for that purpose in patients with chemotherapy-induced leukocytopenia)

Lithium has been used for cluster headache, may be used in CTE

Titrate to blood levels .4 to .8 for maintenance. .8 to 1.2 for acute Tx; toxicity at 1.5 or higher

Dose-dependent side effects include nausea, sedation, weight gain, tremor, acne, polyuria, polydipsia, xerostomia

Bipolar disorder: the mood stabilizers

- ▶ **Lamotrigine (Lamictal)**
- ▶ more efficacious for depression than mania
- ▶ slow titration lessens risk of Stevens-Johnson syndrome
- ▶ Second line Tx after Lithium in Psychopharmacology Institute review
- ▶ used for affective instability in borderline personality disorder

Pop quiz

- ▶ All of the following are true **except**:
- A. **Depakote** (valproate) – better for rapid-cycling mania
- B. **Lithium** – perilously low "Therapeutic Index"
- C. **Lamictal** (Lamotrigine) – rare but serious rash reaction
- D. **Topamax** (Topiramate) – risk of weight gain
- E. **Latuda** (Lurasidone) – good for bipolar depression
- ▶ Answer: D



PTSD

PTSD paradigms




- ▶ Neurobiological
 - ▶ Limbic hyperarousal
- ▶ Behavioral psychology
 - ▶ Classical conditioning
- ▶ Existential/experiential
 - ▶ Shattered assumptive world

PTSD

Neurobiological aspects:

- ▶ **Neuro-anatomical**
 - ▶ Amygdala, hippocampus, anterior cingulate gyrus
- ▶ **Neuro-endocrine**
 - ▶ Cortisol, HPA axis; NPY is protective
- ▶ **Neuro-transmitters**
 - ▶ Catecholamines (NE), 5HT projections, Glutamine



In terms of the neurobiology of PTSD, it's somewhat complex and I won't try to review it here, but rather to note there are three aspects. The neuroanatomy involves the crucial role of the Amygdala, in charge of "fear signaling" in the brain, which is considered overactive in PTSD; the hippocampus, which involves memory and learning. There was a finding of hippocampal atrophy early on in brain imaging of PTSD and researchers speculated that PTSD shrunk the hippocampus, preventing new learning and leaving the patient "stuck" in a repetition of the paralyzing fear of the original trauma. However, subsequent studies, including twin studies of one twin with PTSD and the other without combat exposure, suggested that reduced hippocampal volume was pre-existing. In other words, a risk factor for PTSD and not a consequence of PTSD. A small hippocampus is associated with low intelligence, which is also a risk factor for PTSD. The hippocampus is involved in "the contextualization of trauma" – putting upsetting events into an understandable context that the mind can assimilate into the fabric of everyday experience and move on with life, and a smaller hippocampus correlates with impaired contextualization of trauma. The anterior cingulate gyrus is up in the cortex and serves to put the brakes on the amygdala and tone down the fight or flight response.

The neuroendocrine aspect of PTSD is significant, including increased production of


CRH, which goes to many areas in the CNS and triggers catecholaminergic excess, as well as disrupting the usual hypothalamic-pituitary-adrenal axis feedback loop. As a result, there is an initial surge of cortisol, causing excito-toxicity of the ACG, disrupting the normal inhibition of the amygdaloid fear signaling. In terms of the neuro-endocrinology of PTSD, there's also a role for endogenous opioids. In fact it has been shown the combat casualties who received larger doses of morphine on the battlefield are subsequently less likely to develop PTSD

With all these brain regions and systems activated in threat detection and threat management activities, you can easily see how a number of now-familiar neurotransmitters are involved in PTSD, leaving a potential therapeutic role for serotonergic, norepinephrinergic, and other psychotropics. By the way, we should note that GABA receptors are located diffusely throughout the cortex. Therefore the benzodiazepines, which potentiate GABA, are sedating the very parts of the brain that we need to activate, in order to balance and tone down the amygdaloid and limbic overactivity. This correlates with clinical experience that shows that benzodiazepines are not an effective treatment for PTSD.

PTSD

Treatment principles:

- 1) **Control of nightmares and sleep disturbance**
 - ▶ Prazosin (minipress) and Trazodone
 - ▶ Doxazosin, another alpha-blocker
 - ▶ Remeron clinically useful
- 2) **5HT projections to amygdala and Hippocampus**
 - ▶ Rx: Paxil, Zoloft
- 3) **Mood stabilizers may play a role in Tx but VPA ineffective in studies**
- 4) **Why not lithium for neuro-protective effects?**



This graphic is interesting in that, if you can follow it, it shows that the initial emotion of fear – that which is experienced during the initial traumatizing event, involves cortical or conscious systems including the ACC and VMPFC. But the re-experiencing of the trauma can involve limbic and other subcortical structures only – the PAG, amygdala, and hippocampus. Thus symptomatic episodes can involve the emotion of fear that has been triggered by some stimulus, without any conscious perception of what the fear is all about.

A hallmark of PTSD is sleep disturbance and nightmares. Without sleep disturbance and / or nightmares, whatever post-traumatic symptoms experienced are far less debilitating. Therefore the psychopharmacology of PTSD begins with normalizing sleep and reducing nightmares. Prazosin, an “alpha-blocker” (remember the familiar term “beta-blocker”), is an NE antagonist. It was originally developed for control of high blood pressure but it turned out it wasn’t very good as after a few days the arteries compensating for the anti-adrenergic vasodilation and BP returned to previous levels. However, some PTSD folks reported improved quality of sleep and fewer nightmares, and once again, a new field of psychotherapeutics was born. A second-line treatment for sleep in PTSD is trazodone.


Doxazosin has less penetration of the BBB but the advantage of a longer half-life with easier once a day dosing and may be an alternative. Doxazosin was originally developed for treating urinary hesitancy associated with BPH.

The next big treatment step in PTSD is the addition of an SSRI, owing to serotonergic innervation of the hippocampus and amygdala. Probably any SSRI will do, but Paroxetine and Sertraline have been the most studied.

There is some evidence that the TCA's, Seroquel, and as mentioned the Benzodiazepines may worsen PTSD symptoms, because we don't want to oversedate the part of the brain – the cortex – that is needed to be thoughtful and active and counterbalance an overactive limbic system.

The SGA's should generally be reserved when dissociative or thought disorder (paranoid) or transient hallucinatory (“hearing the screams of wounded soldiers”) symptoms are present.

Meds for ADHD



Neurobiology of ADHD: not completely understood;

80% of variability in ADHD determined by genetics;

DA & NT are the implicated neurotransmitters;

Hypofunction in the PFC;

Sex differences: boys more likely to have hyperactive Sx, girls more likely to have primarily inattentive symptoms.

We do know that the frontal lobes are involved, specifically the PFC and ADHD some say, maybe should be renamed "RIDD" or response inhibition deficit disorder"

The cerebellum, interestingly, is also implicated; might have something to do with chronobiology, as we know that ADHD patients have a really bad sense of time.

So while psychosocial and psychoeducational treatments are important, we have to start from the premise that a biological disorder deserves a biological treatment.

Meds for ADHD

Common Medications			
Type of medication	Brand name	Generic Name	Duration
Short-acting amphetamine stimulants	Adderall	Mixed amphetamine salts	4 to 6 hours
	Dexedrine	Dextroamphetamine	4 to 6 hours
	Dextrostat	Dextroamphetamine	4 to 6 hours
Short-acting methylphenidate stimulants	Focalin	Dexmethylphenidate	4 to 6 hours
	Methylin	Methylphenidate (tablet, liquid, and chewable tablets)	3 to 5 hours
	Ritalin	Methylphenidate	3 to 5 hours
Intermediate-acting methylphenidate stimulants	Metadate CD	Extended-release methylphenidate	6 to 8 hours
	Ritalin LA	Extended-release Methylphenidate	6 to 8 hours
Long-acting amphetamine stimulants	Adderall-XR	Extended-release amphetamine	10 to 12 hours
	Dexedrine Spansule	Extended-release amphetamine	6+ hours
	Vyvanse	Lisdexamfetamine	10 to 12 hours
	Concerta	Extended-release methylphenidate	10 to 12 hours
Long-acting methylphenidate stimulants	Daytrana	Extended-release methylphenidate (skin patch)	11 to 12 hours
	Focalin XR	Extended-release dexmethylphenidate	8 to 12 hours
	Quillivant XR	Extended-release methylphenidate (liquid)	10 to 12 hours
	Intuniv	Guanfacine	24 hours
Long-acting non-stimulants	Kapvay	Clonidine	12 hours
	Strattera	Atomoxetine	24 hours

Products are mentioned for informational purposes only and do not imply an endorsement by the American Academy of Pediatrics. Your doctor or pharmacist can provide you with important safety information for the products listed.

Limitations of stimulants:

- (1) Insomnia
- (2) Tics
- (3) Abuse potential

Non-stimulants:

- (1) ADHD-specific (atomoxetine/Strattera) = NSRI
- (2) Anti-hypertensive meds
- (3) Anti-depressant meds

Overall, efficacy slightly lower than stimulants (50 – 60 % vs. 60 – 90 %).

Meds for treating addictions

- ▶ AUD incidence in US: 14%
- ▶ AUD prevalence in US: 30%
- ▶ c. 100,000 alcohol-related deaths per year in US
- ▶ APA recommends MAT for moderate to severe AUD
- ▶ **Naltrexone** – avoid if on opioids
- ▶ **Acamprosate** – renally excreted
- ▶ **Disulfiram** – “aversive” treatment
- ▶ **Gabapentin** – “anti-craving Rx” ?
- ▶ **Topiramate** – weight loss s/e



Comprehensive, evidence-based treatment for AUD includes:

- Inpatient or outpatient Tx
- CBT
- 12 step and 12-step-facilitated Tx
- M.E.T.
- C.R.T.
- Medication Tx
- No Tx

5 medicines are recommended: 3 are FDA-approved, 2 are “off-label”;

[Say out loud the Brand Names of the five medicines]

Reward circuitry & reward deficiency hypothesis




It was hard to find a single good slide off an internet google search illustrating all the brain mechanisms associated with addictive behavior, but we know that rats will press a lever to obtain DA, and some drugs that activate DA regions in the brain, but not for other chemicals and not for saline. If the lever is attached to an electrode that stimulates a few key brain structures, the rat will basically ignore the outside world and keep pressing the level until exhaustion, which is not a bad model for addiction.

The central reward structures in rat and man alike, include limbic structures: VTA and Nacc. Many other brain structures are involved including importantly alerting and memory structures amygdala and hippocampus – after all, you have to be alert to where you might be able to get your fix and remember where and how and with whom you can get high, and to some extent the frontal areas, involving in planning, procuring, and protecting your supply.

However, all this together is called a 'compulsivity circuit' because it trains itself to bypass, or "hijack" the sane, rational, future-oriented frontal regions of the brain. That's why we say the addict's brain (more precisely, the higher part, or human part, of the brain) it "hijacked" in addiction.

One way or another, all drugs of abuse ultimately stimulate DA and the reward centers of the brain. It's hypothesized that – either through genetics or epigenetic experiences or both – people prone to addiction have a deficient reward circuitry, are therefore vulnerable to seeking exogenous drugs or reward-generating behavioral routines (food, sex, shopping, gambling, etc.), in order to squirt out enough DA to feel okay. This is known as the “reward deficiency hypothesis” of the addictive brain.

Neurobiology of alcohol abuse: neurocircuitry & neurotransmitters



More recently, the NIAAA is focused on looking at 3 neurocognitive states that characterize the addicted brain in order to target drug development for addictive disorders:

Intoxication

Withdrawal

Craving & pre-occupation

Each state has a corresponding NT and circuitry



Provides targets for treatment

Explains why the addicted person you're talking rationally with one moment throws all that out the window the next moment: which "brain" are you really talking to?

There's a medicine called "contrive" for weight loss and a patient of mine remarked

offhand, “funny, since I started the contrive, I don’t have any desire to drink alcohol any more” (Bupropion + Naltrexone).

The Wonderful World of MAT for Opiates: A world of antagonists but no protagonist?



In great literature or drama, there is always a Protagonist and an Antagonist; but in the Wonderful World of Psychopharmacology, there are only Agonists, Antagonists, and “Partial Agonists”:

Naloxone = Antagonist



- Short-acting
- Strips the opiate off the opiate receptor
- For “opioid-reversal” in acute overdose
- Reverses respiratory depression
- Opiate blockade lasts for 30 minutes
- Therefore overdose with long-acting opioids (e.g., Methadone) may require repeated (IV, IM, Intranasal) doses of Naloxone
- Brand name = Narcan
- Side effects: immediate opiate withdrawal, hepatic effects

Naltrexone = Antagonist

- Used for relapse prevention
- Takes hours to take effect
- Opiate blockade lasts for 24 to 48 hours

- Orally effective
- Brand name = ReVia

The Wonderful World of MAT for Opiates: agonist - antagonist –partial agonist



In great literature or drama, there is always a Protagonist and an Antagonist; but in the Wonderful World of Psychopharmacology, there are only Agonists, Antagonists, and “Partial Agonists”:

Naloxone = Antagonist


- Short-acting
- Strips the opiate off the opiate receptor
- For “opiate-reversal” in acute overdose
- Reverses respiratory depression
- Opiate blockade lasts for 30 minutes
- Therefore overdose with long-acting opioids (e.g., Methadone) may require repeated (IV, IM, Intranasal) doses of Naloxone
- Brand name = Narcan
- Side effects: immediate opiate withdrawal, hepatic effects

Naltrexone = Antagonist

- Used for relapse prevention
- Takes hours to take effect
- Opiate blockade lasts for 24 to 48 hours

- Orally effective
- Brand name = ReVia

Disulfiram (Antabuse)



- ▶ Does NOT target the main NT's involved in addiction
- ▶ Blocks alcohol metabolism leading to accumulation of a toxic intermediary metabolite like formaldehyde
- ▶ Symptoms include nausea, vomiting, tachycardia, weakness, hypotension, splitting headache, or seizures
- ▶ Should be taken daily
- ▶ Also blocks DA-decarboxylase; can result in psychosis in vulnerable patients

Disulfiram is unlike other anti-dipsotropics

The Wonderful World of MAT for Opiates: agonist - antagonist –partial agonist

Antagonist

Naloxone (Narcan)

- Neutralized by the liver
- Therefore only IM or IV or IN
- Ultra short-acting

Naltrexone (ReVia)

- Orally effective medication
- Once-daily dosing

IM Naltrexone (Vivitrol)

- Monthly dosing

Partial Agonist

Buprenorphine (Subutex, Temgesic)

- Modest analgesic activity

Buprenorphine + Naloxone SL (Suboxone)

- The Naloxone component rendered ineffective by the liver
- So in theory cannot be diverted for IV abuse

Agonist

Methadone

- Longer-acting
- Slower-onset
- Lowers dysfunction, antisocial activities associated with opiate abuse
- Aligns with the biological, "reward deficiency" hypothesis of addiction

In great literature or drama, there is always a Protagonist and an Antagonist; but in the Wonderful World of Psychopharmacology, there are only Agonists, Antagonists, and "Partial Agonists":

Trick question: which of these are considered "narcotics" ?

Naloxone = Antagonist

- Short-acting
- Strips the opiate off the opiate receptor
- For "opioid-reversal" in acute overdose
- Reverses respiratory depression
- Opiate blockade lasts for 30 minutes
- Therefore overdose with long-acting opioids (e.g., Methadone) may require repeated (IV, IM, Intranasal) doses of Naloxone
- Brand name = Narcan
- Side effects: immediate opiate withdrawal, hepatic effects
- Oral to parenteral ratio = 50:1, meaning that Naloxone is effectively eliminated from the body by "first pass" metabolism in the liver

Naltrexone = Antagonist

- Used for relapse prevention
- Takes hours to take effect
- Opiate blockade lasts for 24 to 48 hours
- Orally effective
- Brand name = ReVia
- Extended-release injectable = Vivitrol

Meds for AUD: considerations on when to use which

Naltrexone

- > Co-occurring alcohol and opioid use disorder
- > Renal impairment
- > Maybe weight loss, too
- > Long-acting form now available as a monthly IM shot

Acamprosate

- > Hepatic cirrhosis or impairment
- > Patient needs to take, or continues to abuse, opioids

Others

- > PRN use for special circumstances (Antabuse)
- > **Topamax** is an acceptable alternative to Naltrexone or Acamprosate
- > **Gabapentin** is an acceptable alternative to Naltrexone or Acamprosate
- > **Topamax** may help with weight loss, too
- > **Varenicline (Chantix)** for smoking helps AUD in men

Alcohol / AUD pharmacology involves:

Opioid pathways (opioid agonists, antagonists, and partial agonists)

GABA and Glutamate pathways (Benzo's & Acamprosate)

None of the above: Antabuse (an "aversive" = targets two-step metabolism of alcohol: alcohol & aldehyde dehydrogenase)



APA (psychiatry) practice guidelines for medication Tx of AUD, Jan 2018

Naltrexone FDA approved 1994 (a commentary on the pace of assimilation of medical knowledge and practice)

Campral (Acamprosate) FDA approved 2004

Antabuse FDA approved around 1948

Case history



Sleep

Approaching insomnia

- ▶ FDA approves drugs for "primary insomnia"
- ▶ "Primary insomnia" accounts for 10 to 15% of all insomnia
- ▶ 85 to 90 % of insomnia is associated with an underlying condition
- ▶ Look for the underlying condition and treat it
- ▶ Always use counseling
 - ▶ Sleep hygiene
 - ▶ Holistic approach from the moment of awakening
- ▶ What makes for an ideal "hypnotic"?



One should never begin with the notion of addressing insomnia by prescribing a pill; rather, one should take a strategic and holistic approach to insomnia.

What makes an ideal hypnotic

- ▶ Rapid onset of action
- ▶ Long – but not too long – duration
- ▶ Normal sleep architecture
- ▶ Safe in overdose
- ▶ No daytime “hangover”
- ▶ Doesn't interact with other psychotropics
- ▶ Non-addictive
- ▶ Does not cause parasomnias
- ▶ “Good for chronic as well as acute insomnia”



Medicines for sleep and medicines for anxiety overlap a lot

- ▶ **FDA approved for insomnia**
 - ▶ Benzo's
 - ▶ "Z" drugs (formerly "BRA" drugs)
 - ▶ Ramelteon (melatonin-like)
 - ▶ Doxepine
 - ▶ Suvorexant (anti-Orexin)
- ▶ **"Off-label" hypnotics**
 - ▶ Sedating antidepressants
 - ▶ Sedating antipsychotics
 - ▶ Sedating anticonvulsants
 - ▶ Antihistamines





The "Z" drugs are "BRA" drugs = benzodiazepine receptor agonists or "BRA" ; it becomes obvious why they changed the nickname to the "Z" drugs =

Zolpidem

Zaleplon

Zopiclone & Eszopiclone

Melatonin, Orexin, Ghrelin



Some hormones the brain manufactures only while awake, sleeping, or in darkness:


Melatonin

Orexin (Hypocretin)

Ghrelin

Benzodiazepines

- ▶ Over 50 BZ's on the market
- ▶ "Biotransformation" = common active, intermediate metabolite
- ▶ Some BZ's bypass this metabolite and don't show up on urine screening
- ▶ Half-life fiascos:
 - ▶ **Flurazepam (Dalmene)** 40-80 Hrs
 - ▶ **Triazolam (Halcion)** 2-5 Hrs
- ▶ Ultra-short acting: **Midazolam**
- ▶ **Flunitrazepam = Rohypnol**



Midazolam = Versed

Flunitrazepam = severe amnesia & psychomotor impairment

Benzo adverse effects

- ▶ Daytime sleepiness
- ▶ Decreased psychomotor performance
- ▶ Anterograde amnesia
- ▶ Rebound insomnia
- ▶ Abuse & dependence
- ▶ Respiratory depression & death


- ▶ **Modafinil (Provigil)** = a "wakefulness-promoting agent"
 - ▶ DA agonist



Predator on benzo's: not exactly
King of the Jungle

The hidden epidemic

- ▶ Opiate overdoses making headlines
- ▶ Benzodiazepine overdoses have increased over the same time period
- ▶ Most common drugs involved in lethal overdose include
 - ▶ Opiates (heroin)
 - ▶ Benzodiazepines
 - ▶ alcohol





Other anxiolytics

- ▶ A few specially developed meds, but mostly non-BZ meds with coincidental sedating properties
- ▶ **Vistaril (hydroxyzine)**
- ▶ **Buspirone (BuSpar)**
- ▶ **Compazine (Prochlorperazine)**
- ▶ **Beta-blocker: Propranolol (Inderal)**
- ▶ In the old days: barbiturates

BuSpar: odd mechanism, DA & 5HT activity; takes weeks to take effect; with MAO-I's get hypertensive crisis; considered too mild for some.

Caffeine: xanthine derivatives



Occurring naturally in more than 60 plants, caffeine is a bitter substance that when consumed has stimulant properties.. Caffeine is the most widely consumed stimulant drug in the world. Caffeine induces feelings of alertness and increased energy as a result of its interactions with adenosine receptors in the brain. Caffeine is also commonly added to pain relief medication because of the role of adenosine in headaches and migraines.

Adenosine is an inhibitory neurotransmitter in the CNS that regulates sleep-wake cycles. When you are awake, adenosine accumulates in the brain and eventually causes drowsiness by attaching to cells in the basal forebrain and inhibiting their activity. Adenosine stimulates signals that tell your body it is time to rest, and activates the responses necessary to engage in full and sustained sleep.

Caffeine and Adenosine

Caffeine's effects of increasing energy and making you feel more alert are due to its interaction with adenosine receptors in the brain. Both caffeine and adenosine are neurotransmitters belonging to a chemical group known as xanthine. In your brain, caffeine appears as adenosine to nerve cells and is able to bind to adenosine receptor sites. As a result, your brain does not detect adenosine, and nerve activity does not

slow down. Instead, caffeine increases brain activity, making you feel more energetic and less sensitive to your body's natural rhythms of wakefulness and sleep.

Your body responds to blocked adenosine by increasing neural activity

Coffee, by the way, is the number one source of anti-oxidants in the US diet. Antioxidants prevent oxidative, or free radical, damage to cells. Coffee contains anti-oxidant phenols, esters, and chlorogenic acid and prevents cancer, cognitive decline, and diabetes.



Part 4: The end

- ✓ INTEGRATING PSYCHOLOGICAL AND BIOLOGICAL PERSPECTIVES
- ✓ QUESTIONS PATIENTS WILL ASK YOU, THE DOCTOR
- ✓ THE PSYCHOLOGY OF PSYCHOPHARMACOLOGY (NON-ADHERENCE)

Questions your patient is likely to ask

- ▶ How fast do the medications work?
- ▶ When is it time to try a different medicine?
- ▶ How will I know when it is working?
- ▶ How does the medicine work?
- ▶ Will I become dependent on it?
- ▶ Will I become addicted to it?
- ▶ Will it turn me into a Zombie?
- ▶ What happens if I stop taking it all of a sudden?
- ▶ Can I get better without medication?
- ▶ What causes depression [or other diagnosis]?
- ▶ Is there a test for depression [or other diagnosis]?
- ▶ Can I smoke weed/drink alcohol while on this medicine?

One study from the British Journal of Psychiatry found that over 50% of patients, when asked if they have any questions, have none at all; of a sample of 200 patients, 57% of patients diagnosed with unipolar depression had no questions about their medication; the group with the most questions about meds was, not surprisingly, those diagnosed with an anxiety disorder: only 7% percent of that sample had no questions about meds for their doctor.

So be prepared not only to answer a variety of questions, but also for the possibility your patient will ask no questions at all.

Questions your patient is likely to ask (slide 2 of 2)

- ▶ Will it make me fat?
- ▶ If I take this medicine, does that mean I'm crazy?
- ▶ What time of day am I supposed to take it?
- ▶ What are the side effects?
- ▶ What happens if a person who doesn't have depression takes this medicine?
- ▶ What about SAmE / St. John's Wort / Melatonin / light therapy?
- ▶ What happens if I miss a dose?
- ▶ Why did the other doctor have me on a different medicine?
- ▶ Is it okay to drive / have sex / get pregnant / play golf while on this medicine?
- ▶ Will it show up on a drug test?
- ▶ "I feel like it's kind of a crutch ..."

"If I take this medicine, does that mean I'm crazy?" = gets at the issue of "stigma" associated with mental illness.

“Is it biological or psychological?”

Biological

- ▶ “endogenous”
- ▶ Strong Family history
- ▶ No premorbid personality factors
- ▶ Prominent **vegetative** symptoms
- ▶ Inflammatory markers present
- ▶ Cortisol non-suppression
- ▶ “limbic instability”
- ▶ **“The brain is the organ of the emotions & you have a chemical imbalance, just like diabetics have a glucose imbalance”**
- ▶ **Rx: ECT & drugs**

Psychological

- ▶ “precipitated”
- ▶ No identifiable family history
- ▶ High neuroticism or perfectionism
- ▶ Prominent **cognitive** symptoms
- ▶ Absence of inflammatory markers
- ▶ Negative dexamethasone suppression test (DST)
- ▶ “negative attribution bias” or “maladaptive early attachments”
- ▶ **“Life is a journey of continuous growth that is sometimes joyous and sometimes tragic, and you have some major life challenges to work through”**
- ▶ **Rx: counseling & environmental change**

Systemic inflammation: cytokines, TNF, Interleukins, CRP,ESR

Vegetative symptoms: appetite, energy, psychomotor changes, diurnal variation

“positive DST” = can’t turn off the stress hormone cortisol; may be correlated with probability of relapse, risk of suicide. Un-moderated Cortisol causes apoptosis of neurons in the hippocampus (“excitatory neurotoxicity of limbic structures”); ketamine, Magnesium, Lithium induce synaptoneogenesis of cortical and hippocampal neurons.

Psychological theories of depression are varied; they include learned helplessness, needs-fulfillment, interpersonal theories (including role strain, interpersonal conflict, and loss), negative self-concept and/or negative cognitive bias.

Biological theories include the biogenic amine hypothesis, fronto-limbic imbalance, inflammatory states, and the neurotrophic hypothesis.

This is an antiquated dichotomy and “the truth is somewhere in between”. Mind and brain are more integrated; psychological experience modifies brain structures and

connections (e.g., hippocampal atrophy in PTSD) and biological variables impact psychological experience (e.g., oxytocin production and interpersonal trust and comfort).

Special concerns about patient adherence to psychiatric meds

- ▶ Diminished self-control or discipline due to the effects of mental illness
- ▶ Medicines have side effects
- ▶ Therapeutic effects take weeks to appear, but side effects appear promptly
- ▶ Family, friends, old-school AA are judgmental about taking meds for psychiatric disorders
- ▶ Increased angst about medicines that are designed to affect or alter the mind
- ▶ Taking psychotropic medication is symbolic of an existential statement about one's metaphysical self-concept and alters one's self-identity

RX:

- (1) Normalize the challenges of daily meds compliance
- (2) Use “MI” techniques to assess patient’s readiness for daily compliance (“on a scale of 1 to 10, how likely are you to take it each day?”“what are the reasons pro and con to take or not take your medications” ...“what are the possible obstacles or impediments to taking your meds each day”
- (3) “why do you think it that you’ve got this whopping depression on your hands?”
- (4) “what are your concerns about being on meds?”
- (5) “what does it mean to you to be a person taking medicine to treat depression?”
- (6) Provide encouragement: we’re all born with diferent brains; all brains have pluses and minuses; (compare to a heart or a larynx or a GI tract); we’ve got to learn to live with and work with the brain we were born with ...”

Suicide rates

- ▶ General population: 13 per 100,000 = 1 out of every 60 deaths = 1.7% of all deaths (nimh.nih.gov)
- ▶ Schizophrenia: 5% = 1 out of every 20 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951591/>)
- ▶ Bipolar disorder: 5% = 1 out of 20 (mentalillnesspolicy.org)
- ▶ Depression:
- ▶ Anxiety disorder:
- ▶ Substance abuse: 7% = 1 of every 14 (ncbi.nlm.nih.gov/pmc/articles/PMC2872355/)
- ▶ Drug overdose in 2016: 2.4% of all US deaths = 1 of every 45 deaths
- ▶ *Body dysmorphic disorder:*

U.S. death rate overall = 824/100,000 (source: <https://www.cdc.gov/nchs/fastats/deaths.htm>)